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Abstract 
 
Introduction 
Hypoxia Inducible Factor 1α (HIF 1α) plays a major role in the pleitropic response 
observed secondary to hypoxic conditions in tumours. Its expression in the tumour 
cells has been correlated to tumour aggressiveness but its prognostic value in 
squamous cell carcinoma (SCC) of the oesophagus remains unclear. To date, limited 
information is available on the prognostic role of HIF 1α in SCC of oesophagus in 
UK population. This information may help in choosing appropriate therapeutic 
strategies and possibly developing a monoclonal antibody with therapeutic potential 
targeting the HIF 1α.  
Methods 
Tumour samples from 36 patients diagnosed with SCC of oesophagus were collected 
in this prospective observational study. Prepared tissue sections were stained with 
validated specific monoclonal antibodies for HIF 1α in controlled experiment and the 
expression of HIF 1α was scored by blind assessment. This expression score was 
correlated with the disease pattern and survival over a period of 4 year 8 months. 
Results 
Out of 36 patients, 17 patients showed low and 19 high expression of HIF 1α. A 
trend of better median overall survival was observed in the group with low 
expression of HIF 1α compared to high expression (238 vs. 196 days) but this was 
not statistically significant (p>0.05, log rank test). Regression analysis showed that 
HIF 1α was not an independent prognostic factor for survival (p>0.05). 
Absence of metastases at diagnosis (p = 0.05) and treatment with curative intent (p = 
0.001) were statistically significant prognostic factors on univariate analysis; on 
multivariate analysis, treatment with curative intent was the only independent 
statistically significant prognostic factor (p < 0.001). 
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Conclusion 
HIF 1α expression did not show prognostic value in SCC of oesophagus in present 
study in spite of a trend in improved survival, in agreement with previous studies. 
Further study is required to support this observation. 
Similar knowledge on the role of HIF 1α expression in oeosphageal adenocarcinoma 
is scarce. As the incidence of adenocarcinoma is increasing, research in this field is 
recommended. Novel strategies on the therapeutic manipulation of HIF 1α in cancer 
are to be explored further and may have a role to play in improving treatment 
outcome in oesophageal cancer. 
 
 
Key words: Oesophageal squamous cell cancer, Hypoxia inducible factor 1α, 
prognostic factor 
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CHAPTER ONE 
 
INTRODUCTION 
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1.1 Prologue 
Oesophageal cancer has a poor prognosis in spite of advances in diagnosis and 
treatment. There is a constant need for more prognostic information to improve the 
outcome of this disease. The outcome may be improved by identifying potential sub-
populations of patients with better prognosis and targeting them with multi-modality 
therapy where applicable. This strategy also may avoid the significant morbidity 
caused by the intensive neoadjuvant, adjuvant and radical surgery treatment 
strategies in those sub-populations with poorer prognosis, who are unlikely to benefit 
from such treatments and hence can have alternate treatment options with better 
quality of life (QOL). 
The current study aimed at evaluating the role of Hypoxia inducible factor 1α (HIF 
1α) in providing prognostic information about SCC of oesophagus. Information 
about the role of HIF 1α in such UK patient population has not been previously 
reported and the results of this study aim to fill the gap. I hope this study can suggest 
further areas of research for better patient outcome.  
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1.2 Outline of thesis 
I have reported my study in six chapters. In chapter one, I have introduced the 
epidemiology of oesophageal cancer which shows the relevance of this study to the 
target population. The role of prognostic indicators including HIF 1α in oesophageal 
cancer and the ongoing search for better indicators is presented. The applied aspects 
and management of cancer of oesophagus are mentioned. In chapter two, 
methodology used in the study is presented. This included the recruitment of 
patients, collection of samples and their processing towards the identification of HIF 
1α expression. Chapter three contained the results of the present study. The clinic-
pathological and survival data, in relation to the expression levels of HIF 1α is 
presented with the aid of figures and statistical tests. In chapter four, I discussed the 
results and analysed then in comparison with existing literature.  Chapter five 
summarised and concluded the significance of the findings of the present study. 
Future work is discussed in chapter six, including recommendations for further 
studies for advancement of the existing knowledge regarding HIF 1α. 
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1.3 Epidemiology of oesophageal cancer 
1.3.1 Incidence 
Oesophageal cancer is one of the commonest cancers worldwide with an Age-
Standardized Rate of 7.0 cases per 100,000 populations in 2008 (World Cancer 
Research Fund International, www.wcrf.org). Currently oesophageal cancer is the 8
th
 
most common cancer worldwide. Wide geographic and ethnic variation is always 
noted in the incidence of oesophageal cancer. In developing countries it is ranked as 
the 5
th 
most common cancer, while it is ranked as 13
th
 most common cancer in 
developed countries. The Age-Standardized Rate for this cancer in 2008 was 8.7 and 
3.6 per 100,000 of these populations respectively (www.wcrf.org).  
UK has a higher incidence of oesophageal cancer within Europe compared to many 
other nations, with the highest incidence rate in women and the second highest 
incidence rate in men (www.cancerresearchuk.org) among European nations. Over 
all, oesophageal cancer is the 9
th
 most common cancer in UK 
(www.cancerresearchuk.org). In 2007, 5226 males and 2740 females were newly 
diagnosed with oesophageal cancer, with European Age Standardised Rate per 
100,000 populations of 14.4 (95% CI 14 – 14.8) and 5.5 (95% CI 5.3 – 5.7) 
respectively.  As per the latest data available from 2009, the life time risk of 
developing this disease is 1 in 64 for men and 1in 116 for women UK. The incidence 
rate is negligible before the 4
th
 decade of life and reaches a peak in the 9
th
 decade of 
life in both sexes. However the highest numbers of cases are seen in the 8
th
 decade in 
males and towards the end of 9
th
 decade in females (www.cancerresearchuk.org), 
making this a disease of the aging population. There is a clear north/south divide in 
UK with the highest incidence in Scotland and some areas of the North of England 
(Quinn et al, 2005). 
There has been a gradual increase in the incidence rate of oesophageal cancer over 
the last 25 years (www.cancerresearchuk.org). The rise was seen especially amongst 
men. Their incidence rose from 8.8 per 100,000 populations in 1975 to 14.4 in 2006. 
Comparatively slighter increase in incidence rates was noticed among women in the 
same period, rising from 4.8 per 100,000 populations to 5.7. The causes for this 
difference are probably multifactorial. 
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There are some differences in the incidence and behaviour of the two main types of 
oesophageal cancer, namely adenocarcinoma (ACC) and squamous cell carcinoma 
(SCC). The majority of the oesophageal cancers globally are of SCC type, while 
ACC is more prevalent in developed nations (Quinn et al, 2001). There is a 
significantly higher incidence rate of oesophageal cancer in most deprived groups 
within developed countries. Gilbert et al (2002) in his audit on Scottish population 
showed clear association between social deprivation and SCC but not ACC, which 
supports the role of different aetiological factors in causation of SCC and ACC as 
discussed later. Gender also seems to play a role in the incidence of these two 
different types of cancer. ACC in males was nearly 5 fold to that of females in 1998 
(Newnham et al, 2003) while this gross variation was not seen in SCC.   
1.3.2 Mortality 
Oesophageal cancer is the 6
th
 most common cause of cancer related mortality 
globally and in the UK (Parkin et al, 2005). In 2008, 5026 men and 2580 women 
died due to oesophageal cancer (www.cancerresearchuk.org). The mortality figures 
are highest in the 8
th
 decade for men and 9
th
 decade for women. The current overall 
survival rates after diagnosis of oesophageal cancer are 30% at the end of 1 year, 8% 
at 5 years and 6-7% at 10 years. (www.cancerresearchuk.org). The trend of mortality 
over the years was in parallel to the rate of incidence. The mortality figures per 
100,000 population rose from 8.1 in 1975 to 13.3 in 2008 for men; in women, these 
figures showed a slight rise from 4.8 in 1975 to 5.4 in 2008. These mortality figures 
mirror the incidence of oesophageal cancer in both sexes. 
1.3.3 Oesophageal cancer in local population 
The catchment area for the recruitment of patients for this study was the Cancer Care 
Alliance network region (www.cancercarealliance.nhs.uk). This network was one of 
the 34 cancer networks in England at the time of patient recruitment and covered the 
healthcare organisations and healthcare professionals from Teesside, South Durham 
and North Yorkshire. The James Cook University Hospital was the tertiary referral 
centre for oesophageal cancer for this network region.  
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The incidence and mortality rates of oesophageal cancer in this region during 2003 
are shown in Table 1 below: 
Table 1. Oesophageal cancer in local catchment area (www.ukacr.org) 
 Incidence Mortality 
 Number *EASR  
(95% CI) 
Rank in 
England 
Number *EASR  
(95% CI) 
Rank in 
England 
Men 79 13.5 (10.5 – 
16.5) 
20 83 14 (11 – 17.1) 12 
Women 60 7.4 (5.4 – 9.4) 2 46 5.4 (3.7 – 
7.1) 
11 
*European Age-Standardised Rate for 100,000 populations at risk  
The incidence rate in the local catchment area is the second highest in UK amongst 
women. The mortality rate for both sexes is in the upper 1/3 of the comparative table 
among network regions of England. 
After our study started, the Cancer Care Alliance network merged with the North of 
England Cancer Care Network (NECN) and hence separate figures for the original 
network are unavailable for updating. For NECN in 2008, 403 new cancers were 
reported (266 men and 137 women), with mortality figures of 375 (244 men and 131 
women, www.nycric.nhs.uk). 
1.4 Role of prognostic indicators 
Oesophageal cancer is a disease on the rise with no great improvement in survival 
over the last few decades. The increase in incidence is probably multi-factorial. Life 
style factors like alcohol consumption and smoking are major aetiological 
contributors of oesophageal cancer, especially SCC (Anantharaman et al, 2011) The 
increased consumption of these in recent decades is reflected in the increased 
incidence of this type of cancer. Other aetiological factors such as obesity and gastro-
oesophageal reflux disease (GORD) with resultant Barrett’s metaplasia of the 
oesophagus are increasing in incidence in the Western world, increasing the 
incidence of ACC (Anantharaman et al, 2011). Education of the population about 
cancer symptoms has been making potential patients aware of their symptoms and 
subsequent identification. General Practitioners are identifying possible cancer 
symptoms based on the ‘alarm symptoms’ as advocated by National Guidelines 
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(www.nice.org.uk), leading to the early identification of the cancer through the ‘two 
week referral rule’. In addition, surveillance programmes of patients at risk of 
developing cancer based on the genetic history and pre-malignant conditions like 
Barrett’s metaplasia are contributing for increasing incidence rates. This trend of a 
rise in oesophageal cancer makes it a priority to identify the disease at an early stage, 
and to provide appropriate and timely treatment. 
The minimal improvement in survival rates in spite of major advances in the 
management represents the poor prognosis from this disease. The 5 year survival 
rates for both men and women have increased from 3% in 1971 to only 8% in 2001 
(www.cancerresearch.org.uk). The 10 year survival rates showed a slower trend of 
improvement: for men, 3% (1971) to 6% (2001); for women, 3% (1971) to 7% 
(2001). 
One of the ways of reducing the morbidity and mortality is to improve the prognostic 
efficacy of current investigations in order to predict the individual course of the 
cancer in a particular patient. This prognostic information helps in planning the 
treatment with the aim of providing the best possible care. In the subgroup of patients 
with early resectable disease but with aggressive nature, neo-adjuvant therapy can be 
considered before offering them two-stage oesophagectomy (TSO). If an early cancer 
is found to have high chances of recurrence post-operatively based on histology of 
the tumour, adjuvant therapy can be offered following TSO (Vallbohmer & Lenz, 
2006). In patients with advanced stage of the disease but possibly good biological 
behaviour and prognosis, aggressive multi-modality therapy can be considered in 
place of palliative therapy with the aim of prolonging survival with reasonable QOL. 
Over estimating the spread and malignant potential of the cancer in an individual 
could deprive him or her of the appropriate treatment modalities available. This 
could have a detrimental effect on the disease progression and subsequent mortality 
of the patient. On the other hand, under-estimating the biological staging of the 
cancer may subject the patient to treatment regimens with potential complications 
and side effects (Avery et al, 2007).  
Surgical options for treating oesophageal cancer have significant morbidity and risk 
of mortality. The in-hospital mortality, 30-day mortality and 90-day mortality were 
4.5%, 3.8% and 5.7% consecutively as per the National Oesophago-gastric Cancer 
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Audit 2010 (www.ic.nhs.uk). The post-operative complication rate causing morbidity 
was 29.8%. Oesophageal cancer is a disease of the elderly and subjecting them to a 
major procedure from which they may not benefit is best avoided. 
The potential side effects of chemotherapy for oesophageal cancer include 
immunosuppression, anaemia, increased bleeding tendency, sickness & diarrhoea, 
hair loss and soreness of hands & feet. Radiotherapy to the oesophagus can cause 
sore throat resulting in dysphagia, reduced appetite and malnutrition. These effects 
are worse in older patients. For example, data available from the National 
Oesophago-gastric Cancer Audit 2010 (www.ic.nhs.uk) shows that the proportion of 
patients who completed palliative chemotherapy falls from 60% under 60 years of 
age to 43% in aged 80 years and above. These side effects usually interfere with the 
QOL of the patients and can be minimised by outweighing the benefits of the 
particular treatment over the potential side effects and risks, and offering them only 
to the patients deemed to be benefitting from them. 
The aim of treatment for each patient influences his or her quality of life too. A study 
of QOL using European Organisation for Research and Treatment of Cancer 
(EORTC) validated questionnaires showed that patients of oesophago-gastric cancer 
treated with palliative intent reported worse global QOL (mean score 55) than those 
treated with curative aim (mean score 67; National oesophago-gastric cancer Audit 
2010). They also complained about symptoms like fatigue, nausea and vomiting, 
dyspnoea and appetite loss worse than in those treated with curative intent. While the 
severity of some of these symptoms might be due to the advanced disease itself, the 
modality of therapy would undoubtedly have a part to play. Hence the clinicians 
shall have access to more information about the prognosis of each patient before 
approaching a particular aim of treatment.  
So, it is essential that the best available evidence based prognostic information is 
provided to the clinicians to enable that SCC patients are treated in their best 
interests. Prognostic indicators are the main stay of providing such evidence. The 
pros and cons of the various prognostic indicators of SCC and their current usage are 
discussed below.   
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1.4.1 Current prognostic indicators 
A wealth of information is currently available about prognostic indicators of SCC. 
Evidence based medicine (EBM) provides guidance on which of these indicators 
could be accepted into clinical practice to obtain useful information about disease 
behaviour. This information forms a basis for multidisciplinary team (MDT) 
discussions, clinical audits and as a tool to measure outcomes of the disease. These 
are discussed under clinical prognostic indicators. 
Many in vivo and in vitro studies provided useful information on the prognostic value 
of various molecular compounds in relation to human cancers, and in particular to 
SCC. These compounds do have potential value to provide prognostic information 
that can be utilised for clinical application if stronger evidence is provided. I 
discussed them further as molecular prognostic indicators.  
1.4.1.1 Clinical prognostic indicators 
1.4.1.1.1 TNM (Tumour, Node, Metastasis) Staging 
Currently TNM staging is the best available evidence based prognostic indicator in 
universally accepted practice. The TNM staging system for malignant tumours was 
originally compiled by Pierre Denoix in 1946. The first comprehensive classification 
for various tumours was published in 1968 by UICC (International Union Against 
Cancer). The TNM classification and staging for oesophageal cancer is described in 
detail in 1.5.3.2 and can be briefly mentioned as two separate classifications, clinical 
and pathological. 
The clinical TNM classification is based on the evidence pertaining to the anatomical 
tumour spread. The various staging investigations as mentioned later provide this 
evidence. The clinical TNM stage at the time of diagnosis is used as a practical basis 
to plan the treatment of the particular individual and provides some prognostic 
information as to the likely course of the disease. The pathological classification is a 
better provider of information than the clinical TNM stage alone, and is based on the 
supplementary histological information available from a resected tumour specimen. 
These histopathology based indicators are the grading of the tumour, pathological T 
N M staging (pT, pN and pM), and the number of lymph nodes resected. Therefore 
the pTNM staging has obvious superior prognostic value compared to the clinical 
stage, and helps plan the postoperative management. TNM staging guides to the 
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appropriate intent of treatment for a particular individual, modality of primary 
treatment, extent of resection of involved organ where surgery is chosen, response to 
the primary treatment, and decision making regarding neoadjuvant treatment 
(Mackillop et al, 1998). In addition, staging guides research on tumour management 
and helps manage cancer control programmes. 
Current TNM staging for oesophageal cancer is not foolproof though. Significant 
difference between the assessments of spread of upper oesophageal cancer by clinical 
and pathological TNM stagings was shown by Peracchia et al (1990). Their study 
showed that the clinical TNM staging of cervical oesophageal cancer was not in 
agreement with the pathological TNM stage in nearly 50% of the cases. They felt 
that the clinical TNM staging alone is hence inaccurate and unreliable for therapeutic 
decision making and estimating prognosis in patients with cancer in the cervical 
oesophagus. There is a dearth of information about the accuracy of TNM staging in 
oesophageal cancer affecting other regions of oesophagus.  
Another limitation of TNM is that complete pTNM staging information is only 
available in patients undergoing surgical resections of their oesophageal tumours; a 
significant number of patients do not fit into this category. Large numbers of patients 
present at a later stage of the disease due to minimal symptoms from the tumour and 
hence are not suitable for resection. Patients with cancer beyond T3N1 stage are 
considered advanced and curative resection is not attempted in this group. The 
majority of the patients are also elderly with significant co-morbidities, which have 
major implications for the management of their disease. Poon et al (1998) have 
shown that resection rate for oeosphageal cancer in patients aged above 70 years is 
48%, in contrast to younger patients with a resection rate of 65% (p<0.001). Their 
study also showed that the post-operative complications arising from associated 
medical conditions are also much higher in the older age group. Zehetner et al (2010) 
studied 560 patients of oesophageal cancer who underwent curative surgery over a 
period of 15 years and showed that only 8% of this group are aged 80 years and 
above. While the results of the operation including survival rates in those aged above 
80 years were similar to younger patients in their study, there was a careful patient 
selection based on their cardiopulmonary status that made these results possible. 
Contrasting results were shown by Braiteh et al (2009) who showed that the 
complications and survival following surgery is worse in patients aged above 70 
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years compared to younger patients and this still seems to be the general opinion 
among surgeons. Recent studies showing similar survival rates with either surgery or 
chemo-radiation in patients aged above 70 years (Davies et al, 2010) influence the 
current management opinions regarding this group of patients. 
This stresses on the need for very careful selection criteria for the surgical 
management in the elderly. Many centres including the one where the current study 
was carried out do not generally consider elderly patients for elective curative 
surgery and hence pTNM information which is more accurate is unavailable in a 
significant number of patients. This limits the usefulness of TNM staging system and 
supports search for a better prognostic marker, which can provide useful information 
across the patient groups with no undue dependence on the mode of treatment.  
The number of involved lymph nodes alone has independent prognostic value, which 
was not considered as a criterion in the current TNM staging. Prognostic systems 
based on the number of involved lymph nodes (0, 1 - 3, or >3) or ratio of involved to 
normal looking lymph nodes (0, <0.15, or >0.15) were shown to be of help in 
assessing the prognosis of patients who underwent TSO (Van Sandick et al, 2002; 
Wijnhoven et al, 2007). The number of metastatic lymph nodes counted during 
endoscopic ultrasound (EUS), known as endoscopic lymph node metastatic count 
(eLNMC) has shown significant independent prognostic value in a recent study from 
Cardiff (Twine et al, 2010). Kato et al (2009) showed that the number of metastatic 
lymph nodes identified by Positron Emission Tomography (PET) scan has 
independent prognostic value regarding disease free and overall survival. The current 
TNM staging does not take these into account for staging purposes. Griffiths et al 
(2006a) criticised TNM staging system for not including the number of metastatic 
lymph nodes in the staging for cancer of the lower oesophagus and gastro-
oesophageal junction (GOJ). He cites the TNM staging of gastric cancer as an 
example. In gastric cancers, the number of involved nodes determines the N stage as 
pN1 (1-6 nodes), pN2 (7-15 nodes) and pN3 (>15 nodes). His study involved only 
the GOJ tumours, but similar argument can be made for all oesophageal cancers to 
make the current TNM staging a more robust prognostic indicator.   
The other criticism of TNM staging is that the information forming the basis of the 
system is provided mostly by studies on SCC of the upper and middle oesophagus 
(Lagarde et al, 2006a). As the incidence of lower oesophageal ACC is the currently 
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predominant form of this cancer, this information is inadequate and hence a new 
staging system for ACC of gastro-oesophageal junction is proposed to be considered 
by UICC. 
Studies are going on to improve the efficacy of the staging by the addition of various 
parameters through the evidence base. Rice et al (2010) have incorporated 
histopathological type of the cancer, histological grade and cancer location to the 
existing TNM classification to propose a joint AJCC/ UICC staging classification. 
This was shown to provide better prognostic information that TNM alone 
(Wijnhoven et al, 2007) but has not yet been tested in practice. More recently Gaur et 
al (2010) published the staging system recommended by the Worldwide Esophageal 
Cancer Collaboration (WECC) wherein incorporating the number of lymph nodes 
involved with cancer to the AJCC system has shown better prognostic potential for 
ACC of gastro-oesophageal cancers. 
1.4.1.1.2 Other clinical prognostic indicators 
While TNM staging is a main source of prognostic information, there are other 
dependable sources that assist in assessing prognosis. Some of them are currently in 
routine usage for this purpose. 
The extent of tumour removal by TSO plays a major role in future local recurrence 
and has prognostic significance. Involvement of proximal (Mariette et al, 2003a) and 
distal (Casson et al, 2000) margins of the resected specimen by tumour has shown 
poor survival. The involvement of circumferential resection margins (CRM) is 
debatable. Various studies have shown contrasting results of positive CRM on 
survival rates (Khan et al, 2003; Sheepers et al, 2009). This is a possible reflection on 
the extent of mediastinal dissection and hence is surgeon dependent. Khan et al 
(2003) summarised in their review article based on the available literature that in 
those patients who received neoadjuvant chemotherapy, CRM showed independent 
prognostic value, while its role in the surgery alone group was unclear.  
The extent of residual disease left behind (denoted as: R0 = no residual disease, R1 = 
microscopic residual disease and R2 = macroscopic residual disease) has important 
independent prognostic value (Hofstetter et al, 2002; Ott et al, 2009) and is a 
frequently reported parameter following TSO. The patients who had R0 status are 
deemed to have complete removal of the primary tumour and have better prognosis 
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in terms of loco-regional control than R1 status patients. R1, and sometimes R2 
status patients are generally considered for adjuvant therapy to improve the loco-
regional control of the disease. 
The length of the tumour at the time of diagnosis has shown to be of independent 
prognostic value. Griffiths et al (2006b) reported that patients with tumours longer 
than 3.5 cm at histology have a poorer prognosis than those with shorter tumours. 
This may represent a larger tumour volume at the time diagnosis, with possible 
inherent aggressiveness.   
Vascular and peri-neural invasion by cancer cells has shown poor prognosis 
(Watanabe et al, 2000; Brücher et al, 2001) and has independent prognostic value. It 
is considered as part of the histological grading of tumour and again this information 
is available only on resected specimens. Extra-capsular spread of tumour cells in the 
involved lymph nodes is also reported to be of good prognostic value (Yoon et al, 
2010). 
Association with Barrett’s oesophagus either as a precursor or as concomitant feature 
along with ACC has been found to be an indicator of better prognosis. The ACC not 
arising from Barrett’s mucosa is probably of a different histological behaviour; also 
the presence of Barrett’s mucosa and the associated symptoms allow early 
endoscopic identification of the ACC and early treatment, with subsequent better 
results (Menke-Pluymers, 1992). 
The severity of the patients’ symptoms like dysphagia and weight loss was 
traditionally perceived to be a predictor of poor prognosis; there is now evidence to 
support this. Plaisant et al (2005) reported that weight loss is an independent 
predictor of survival in oesophageal cancer patients. Dysphagia was a prognostic 
factor in a univariate analysis (Mariette, 2003b) but did not show independent 
prognostic value. Low serum albumin levels in patients undergoing chemo-radiation 
has shown poorer prognosis in a recent study by Cincibuch et al (2010). Deans et al 
(2006) reported that the tumour inflammatory cell infiltrate and systemic 
inflammatory response as measured by the circulating levels of C-reactive protein 
(CRP) were associated with predicting patient survival.  
With the advent of recent techniques which from an integral part of work-up of 
oesophageal cancers, evidence is emerging about additional prognostic markers. 
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During PET scan, the amount of 18-Fluorodeoxyglucose absorbed by the tumour 
cells can be calculated and this is known as ‘metabolic tumour volume (MTV)’. This 
parameter was shown to be of independent prognostic value in oesophageal cancer 
tumours (Hyun, 2010) with tumours having higher MTV showing worse prognosis.  
On similar lines, during EUS, length of the diseased segment of oesophagus and 
tumour thickness could be measured and the endoscopic ultrasound defined tumour 
volume (EDTV) calculated. This information has independent prognostic value as 
shown by Twine et al (2010a). They studied 174 consecutive patients and showed 
that if the EDTV is less than 25 cm
3
 there was significant survival advantage. 
It is evident that there is potential for identifying more prognostic indicators for 
precise recognition of the behaviour of the cancer. But none of these indicators 
described so far could show strong enough association with survival of the patients 
which was significant enough to employ them on their own in predicting the 
prognosis. Lagarde et al (2006b) suggested Artificial Neural networks (ANN) and 
nomograms to incorporate various other prognostic indicators discussed above, in 
view of the increasing knowledge about the biological behaviour of these tumours. 
This information will arm the healthcare team with the best available knowledge of 
the prognosis of a particular patient and as a consequence assists in decision making.  
Prognostic information available from different markers could also be pooled 
together to determine a score of severity of oesophageal cancer. The Royal Marsden 
Hospital prognostic index is such system based on the pooled data from 1,080 
patients with locally advanced and metastatic gastro-oesophageal cancer enrolled in 
multicentre randomized controlled trials. Based on the presence of four risk factors, 
namely performance status, liver metastases, peritoneal metastases and alkaline 
phosphatase levels, patients are categorized into good (no risk factor), moderate (1 or 
2 factors) and poor (3 or 4 factors) risk groups. Of these, the first three factors have 
independent prognostic value as well. The one year survival rates in these three 
groups were 52.4%, 33.1% and 13.7% respectively. However this index is of not 
much use in early stages of the cancer and in clinical practice may have minimal 
impact on patient management. 
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1.4.1.2 Molecular prognostic indicators 
Several molecular prognostic indicators are currently being studied in oesophageal 
cancer. Some examples are epidermal growth factor receptor (EGFR), angiogenic 
factors (e.g. vascular endothelial growth factor (VEGF), Cox-2 protein, basic 
fibroblast growth factor (bFGF), Transforming growth factor (TGF) α, tumour 
suppressor gene p53, cell cycle regulators (Cyclin D1 protein, p21 protein, p27 
protein), DNA repair system (Excision repair cross complementing (ERCC) 3 
protein), apoptotic factors (ERCC1 gene, Bax protein, Bcl-2 protein and Bcl-X 
protein), matrix metalloproteinases (MMP-7, MMP-9, MMP-2 and MMP-11) and 
Human epidermal receptor – 2/ HER – 2 (Vallbohmer & Lenz, 2006).  
Ogata et al (2003) in their long term follow up study showed that the expression of 
EGFR was positively related to the survival in node positive SCC. EGFR gene 
amplification was also discovered to be a predictor of poor survival in SCC 
(Kitagawa et al, 1996). Recent studies have shown significance of mutations in the 
EGFR gene. The patients with mutation of the EGFR gene caused by single nuclear 
polymorphism at codon 787 of exon 20 showed significantly poorer overall survival 
rates (Kaneko et al, 2010).  
VEGF is a signal protein that induces formation of de novo capillaries 
(vasculogenesis) and proliferation of the existing capillaries (angiogenesis). It plays a 
major role in the survival of tissues in presence of ischaemia, including tumour 
tissues and in subsequent adaptability of the tumour to hypoxia. This reflected in the 
finding of higher T and N stages in oesophageal SCC patients expressing higher 
expression of VEGF (Shih et al, 2000). The tumour microvessel density (MVD) 
which in turn is influenced by the action of VEGF has also showed worse prognosis 
in those with high expression. These two hence have good prognostic potential. 
Cyclins and cyclin dependent kinases (CDK) form a protein-kinase complex which 
participates in the mitotic cycle of the cell during G1 phase. Alterations and 
mutations of the genes controlling these proteins were known to be causative factors 
for tumours. Shinozaki et al (1996) studied the role of amplification of cyclin D1 
gene in oesophageal SCC. They showed the amplification of cyclin D1 gene in 
11q13 region cause significantly lower survival in their study group, stage to stage in 
comparison with those showing normal gene. The occurrence of distant metastasis 
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was also found to be higher in those with gene amplification. P16 is a tumour 
suppressor protein that acts by inhibiting CDK. Loss or low expression of the p16 
gene was found to result in worse prognosis in SCC, with an inverse relation to 
cyclin D1 expression (Tekeuchi et al, 1997). They believed these genetic expressions 
can be utilized as independent prognostic indicators. Similar results were published 
recently by Kawakubo et al (2005).  
p53 is a tumour suppressor gene whose vital role in preventing human cancers was 
discovered in 1989 by Baker et al. Mutations of this gene were shown to be common 
in many visceral cancers. Up to 50% of human tumours show mutation or alteration 
of this important gene (Hollstein et al, 1991). Similar changes were observed in the 
p53 expression of oesophageal tumour cell lines and specimens (Hollstein et al, 
1990). Patients with tumours with allelic loss of both 17p and 18q of the p53 gene 
had worse survival than those who did not (Galipeau et al, 1996). P53 mutations as 
identified by Polymerase chain reaction (PCR) showed significant predictive value in 
the response to chemotherapy of SCC patients. Yamasaki’s study observed objective 
response to chemotherapy in 65.9% of patients with original genotype, but in only 
16.7% of patients with the mutant gene (2010). 
Epithelial cell adhesion molecule (EpCAM), also known as tumor-associated 
calcium signal transducer 1 (TACSTD1) is a component of cadherin-catenin 
pathway. It has shown correlation with tumour depth, stage of the disease, blood 
vessel invasion and survival in oesophageal cancer (Kimura et al, 2007). Cytokeratin 
19 in combination with EpCAM has improved the accuracy of this identification. 
Estimating the expression of various molecular markers in combination may improve 
their overall prognostic accuracy in a similar fashion. 
ΔNp63 (Amplified in SCC or AIS) protein detection in the blood of patients with 
primary and recurrent SCC of oesophagus has shown promising results in identifying 
the presence of SCC cells (Koike et al, 2002). This protein is produced by the ΔNp63 
gene which is a homologue of p53 gene. Regular measurement of this protein may 
help in the monitoring of the patients with known oesophageal cancer. Squamous cell 
carcinoma associated antigen (SCC) and carcinoembryogenic antigen (CEA) have 
limited value in the monitoring of SCC patients, and ΔNp63 expression was found to 
be more accurately associated with this cancer.      
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Ross & McKenna (2001) showed that HER-2/neu oncogene expression on 
chromosome 17q encodes tyrosine kinase growth factor receptor and its 
overexpression is an independent prognostic factor in ACC of oesophagus. But there 
is lack of evidence to attribute the same role to it in SCC of oesophagus. 
Amplified in breast cancer (A1B1) gene over expression (He et al, 2009) was 
associated with distant metastases, late stages of the tumour and resistance to 
chemoradiation in oesophageal SCC. Moreover, this gene overexpression was an 
independent predictor of survival in these patients. 
With the advent of genome mapping, studies were done to detect alterations in 
various genes areas that could help identify the biological behaviour of oesophageal 
SCC. Carneiro et al in 2008 applied array based comparative genomic hybridization 
technique to 30 SCC specimens and detected recurrent alterations in 19% of them. 
They included recurrent gains of up to 60% in chromosome regions 5p, 7p, 7q, 8q, 
10q, 11q, 12p, 14q, 16p, 17p, 19p, 19q, and 20q; losses of up to 40% in regions 3p, 
5q, 8p, 9p and 11q. The number of alterations was also found correlated with the 
tumour stage, degree of differentiation and metastatic potential, with fewer 
alterations in less aggressive tumours. They concluded that there is independent 
prognostic role for gain of 7p22.3 in nodal metastases and gains of 1p36.32 and 
19p13.3 in survival. The genetic profiling may help identify the subset of patients 
with aggressive tumours at a very early stage, with subsequent implications for 
targeted therapy. Further studies are needed to develop a practical application tool 
utilizing this information. 
Hu et al (2009) went further and tried to identify the genes identifiable with 
oesophageal carcinogenesis itself. Their group studied the genomic instability in 
SCC cells from a high risk region of China using genetic arrays and identified 30 
regions with potential carcinogenic genes. High levels of loss of heterozygosity 
(LOH) were observed on selected chromosome arms, which could be targeted to 
identify genes responsible for carcinogenesis. They compared the tumour DNA with 
germ-line DNA obtained from peripheral venous blood and found identical genetic 
changes within each patient’s samples.  
Currently none of these molecular tumour markers are incorporated in the protocol 
for the management of oesophageal cancer and they have no practical application. 
  _____________________________         Chapter 1     
18 
 
The limited choice of available molecular prognostic indicators encouraged our 
current study in evaluating the possible role of an important molecule, Hypoxia 
Inducible Factor 1α in oesophageal cancer of the local population.  
1.4.1.3 Hypoxia Inducible Factor 1α 
1.4.1.3.1 Molecular biology 
Hypoxia inducible factor (HIF) was described by Semenza and Wang in 1992 during 
their studies on the hypoxia response element (HRE) of erythropoietin. They later 
(1993) described the role of HIF in the hypoxic response related activation of many 
genes. HIF has basic-helix-loop-helix (bHLH) structure, and belongs to the PAS 
(Periodic circadian protein, Aryl hydrocarbon receptor nuclear translocator protein, 
Single minded protein) subfamily of transcription factors (Wang & Semenza, 1995a; 
1995b).  
HIF is composed of α and β subunits, and is activated when both the subunits join 
and form a heterodimer. HIF α was known to exist in three paralogues, namely HIF 
1α, HIF 2α and HIF 3α. HIF 1β was initially known as aryl-hydrocarbon-receptor 
nuclear translocator (ARNT) (Semenza & Wang, 1992). This exists as three 
paralogues, ARNT1, ARNT2 and ARNT3. Either HIF 1α or HIF 2α can 
heterodimerise with HIF1β to from functional HIF. The domain structures of HIF are 
shown in Figure 1. 
 
Figure 1. Domain structures of the HIF transcription factors            
(Lisy & Peet, 2008. Reproduced by permission) 
The three HIF α subunits show partially overlapping expression and functional 
patterns both in vitro and in vivo (Lisy & Peet, 2008). HIF 2 and HIF 3 may cross-
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react with HIF 1 target genes, which can lead to either up-regulation of the function 
of HIF 1, or down-regulation by forming inhibitory PAS domain protein or IPAS. 
But their role is still to be defined (Wenger, 2002). 
1.4.1.3.2 Functional structure 
The three HIF α paralogues, HIF 1α, HIF 2α and HIF 3α (including the HIF 3α splice 
variant IPAS, and common binding partner HIF 1β ARNT), all contain N-terminus/ 
domain (NAD/ N-TAD) which is a bHLH domain for DNA binding; central region 
which is PAS domain that facilitates heterodimerization and C-terminus/ domain 
(CAD/ C-TAD) to recruit transcriptional coagulatory proteins (Zhulin 1997; Ponting 
1997; Yang 2005). In addition, all the three HIFα isoforms contain Oxygen-
dependent degradation domain (ODDDs). HIF 1α and HIF 2α each contain oxygen 
regulated CAD. The functional domains of HIF 1 were shown in Figure 2.   
 
Figure 2. Schematic diagram showing functional domains of HIF family members 
HIF-1α, HIF-2α, HIF-3α and HIF-1β          
(Kenneth & Rocha, 2008. Reproduced by permission) 
The modifications of specific residues are highlighted above each protein, and the 
proteins that perform those modifications are shown. Coloured bars below each 
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protein delineate particular interaction regions within HIF proteins (CTAD - C-
terminal transactivation domain; LZIP - leucine zipper; NLS - nuclear localization 
signal; NTAD - N-terminal transactivation domain; PAS - Per/ARNT/Sim domain; 
PAC - PAS-associated C-terminal domain). 
1.4.1.3.3 Regulation of HIF 1α protein levels 
HIF 1α concentration significantly increases as a response to exposure of the cell to 
hypoxia and is mostly Oxygen regulated (Matsumuto et al, 2003). In contrast, HIF 1 
β is constitutively present in the intracellular content and its expression usually does 
not change following exposure to hypoxia (Bardos & Ashcroft, 2004). 
The intracellular levels of HIF 1α are maintained at low levels with a half life of less 
than 5 minutes (Bardos & Ashcroft, 2004) by a balance between its continuous 
production and degradation as shown in Figure 3. 
 
Figure 3. Pathways of HIF 1α regulation (Wenger, 2002. Reproduced by permission) 
During normoxia, the two proline residues (Pro 402 and Pro 564) in HIF 1α are 
hydroxylated, mediated by prolyl- 4- hydroxalase in presence of iron, oxygen and 2 –
oxoglutarate (Jakkola et al, 2001). This is shown in Figure 4. These two proline 
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residues then enable the binding of HIF 1α to the Von Hippel-Lindau tumour 
suppressor protein (pVHL). The carboxyl-terminal trans-activation region of HIF 1α 
is hydroxylated which modifies the asparagine residue Asn803. This phenomenon 
regulates activity rather than stability by interfering with
 
the recruitment of the 
transcriptional coactivator CBP/p300 (Lando et al, 2002).  
 
 
Figure 4. Formation of HIF prolyl hydroxylase (Flashman & Leonarz, Schoffield 
group, Oxford University; www.chem.ox.ac.uk. Reproduced by permission) 
The HIF 1α which is prolyl-hydroxylated is bound to an ubiquitin ligase complex, 
and is subsequently ubiquitinylated and targeted for degradation 
(www.chem.ox.ac.uk). This final step is mediated by the ubiquitin–proteasome 
pathway known as 26S proteasome pathway, resulting in hydrolysis of HIF 1α 
(Maxwell et al, 2001). This is the main and well known pathway of HIF 1α 
regulation in normoxia. 
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During hypoxia, HIF 1α proline residues remain unmodified and hence do not bind 
to pVHL, thus resulting in increased levels of HIF 1α. The HIF 1α then migrates to 
the cell nucleus and dimerises with HIF 1β to form the active transcription factor HIF 
1, which recognises the hypoxia response element (HRE) present in the enhancers of 
several target genes (Ryan et al, 1998) and recruits coactivators (Wenger, 2002): 
Alternate pathways of HIF 1α regulation were described. Regulation of HIF 1α 
stability is also mediated by an oxygen-independent pathway. In the cytoplasm, HIF 
1α is bound by heat-shock protein 90 (Hsp90) and this association leads to enhanced 
stability of the subunit.
 
However, upon displacement of Hsp90 by Hsp90 inhibitors, 
the receptor of activated protein C kinase (RACK1) is able to bind and acts to recruit 
ubiquitin ligase machinery and potentiate the degradation of the α subunit (Lisy & 
Peet, 2008). 
Wenger (2002) reviewed the mechanisms of stabilization of HIF 1α, other than 
pVHL mediated pathway. These are mediated through various agents including 
insulin, insulin like growth factors 1 and 2, epidermal growth factor, fibroblast 
growth factor2, interleukin 1β, tumour necrosis factor, angiotensin 2, thrombin, 
transforming
 
growth factor ß1, platelet-derived growth factor and hepatocyte growth 
factor. Genius and Fandrey (2000) described that nitric oxide initially increases and 
on prolonged exposure inhibits HIF 1α expression.  
It is believed this mode of stabilization of HIF 1α is mediated by via common 
cellular kinase pathways (Wenger, 2002), but the picture is unclear. 
1.4.1.3.4 Activation of HIF 1α 
Once the HIF 1α is stabilised, various further steps are involved in the activation of 
HIF 1α. These include post-translational protein phosphorylation, nuclear 
translocation, ARNT heterodimerization, DNA binding, recruitment of general and 
tissue specific transcriptional cofactors and target gene transactivation, as reviewed 
by Wenger (2002).   
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1.4.1.3.5 Functional mechanism of HIF 1α 
To date, the transcription of more than 70 genes are found to be directly regulated by 
HIF 1α. These genes are involved in cellular processes that act to directly address the 
cellular hypoxia by decreasing oxygen dependence and consumption by cells, and by 
increasing the efficiency of oxygen delivery to cells. These processes include 
vasculogenesis and angiogenesis, metabolism, vasodilatation, cell migration, 
signalling and cell fate decisions and were reviewed by Semenza (2010). They are 
tabulated in Table 2. 
Table 2: Selected HIF 1α target genes, whose products contribute to cancer 
progression (Reprinted by permission from Macmillan Publishers Ltd.: Oncogene, 
Semenza (2010)) 
 
Gene Product Role in cancer progression 
Angiopoietin 2 Angiogenesis, lymphangiogenesis 
Angiopoietin-like 4 Metastasis 
Breast cancer resistance protein 
(ABCG2) 
Multidrug transport, stem cell maintenance 
Carbonic anhydrase 9 and 12 pH regulation 
C-MET Invasion 
CXCR4 Metastasis 
DEC1 Genomic instability 
Endothelin 1 Invasion 
Fibronectin 1 Invasion 
Glucose phosphate isomerase Cell motility, glucose metabolism, 
immortalization 
Glucose transporter 1 Glucose uptake 
Hexokinase 1 and 2 Glucose phosphorylation; cell survival 
Inhibitor of differentiation 2 Angiogenesis, proliferation 
Insulin-like growth factor 2 Cell survival, proliferation 
JARID1B Stem cell maintenance 
Kit ligand (stem cell factor) Angiogenesis, stem cell maintenance 
Lactate dehydrogenase A Glucose metabolism 
Lysyl oxidase Metastasis 
Matrix metalloproteinase 2 and 14 Invasion 
NT5E (ecto-5′-nucleotidase/CD73) Immune evasion, multidrug resistance 
OCT4 Stem cell maintenance 
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Gene Product Role in cancer progression 
Placental growth factor Angiogenesis 
Platelet-derived growth factor B Cell proliferation/survival, angiogenesis 
Pyruvate dehydrogenase kinase 1 Glucose metabolism 
Pyruvate kinase M2 Glucose metabolism 
Stromal-derived factor 1 Angiogenesis 
Survivin Cell survival 
Telomerase Immortalization 
Transforming growth factor α Cell proliferation/survival 
TWIST1 Epithelial-mesenchymal transition 
Urokinase plasminogen activator 
receptor 
Invasion 
Vascular endothelial growth factor Angiogenesis 
WSB1 Cell survival 
ZEB1 (ZFHX1A), ZEB2 (ZFHX1B) Epithelial-mesenchymal transition 
 
1.4.1.3.6 Actions of HIF 1α 
1.4.1.3.6.1 Physiological role 
Many animal experiments demonstrated that HIF 1α is required for mesenchymal cell 
survival during embryonic development. HIF 1α knockout embryos die around mid-
gestation, showing cardiovascular malformations
 
and open neural tube defects (Iyer 
et al, 1998; Ryan et al, 1998; Kotch et al, 1999). Mice containing only
 
one mutant 
HIF 1α allele have shown impaired physiological responses to chronic hypoxia (Yu 
et al, 1999; Shimoda et al, 2001). In partially HIF 1α deficient mice, although the 
ventilatory
 
response to acute hypoxia was normal, ventilatory adaptation
 
to chronic 
hypoxia was impaired as evident by the diminished response to subsequent exposure 
to acute hypoxia (Kline et al, 2002). These results clearly demonstrate the central 
role
 of HIF 1α in the adaptation to hypoxia not only at the cellular but at the systemic 
level.
  
1.4.1.3.6.2 Role in human cancer 
The role of HIF 1α in human cancers is not yet fully understood. But the available 
evidence supports the hypothesis that this factor acts at different levels in the 
causation and progression of cancer (Semenza, 2002).  
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1.4.1.3.6.2.1. Carcinogenesis & cancer progression 
In 1998, Ryan and Johnson studied the role of HIF 1α in the transcriptional activities 
induced by hypoxia. They created a null mutation at the HIF 1α locus in embryonic 
murine stem cells and discovered that these cells fail to up-regulate many HIF 1α 
target genes. The teratomas induced in syngeneic or immunocompromised mice by 
the introduction of these cells were noticed to be only ¼ of the size compared to 
those caused by wild embryonic stem cells. Mice embryos which were homozygous 
for null HIF 1α showed failed yolk sac vascularization, defective neural tube closure 
and apoptosis. Hypoxic regulation of VEGF was also severely affected. They were 
the first authors to report that the embryonal response to hypoxia was regulated by 
HIF 1α. Later on, Goda et al (2003) experimented on murine embryonic fibroblasts 
and splenic B lymphocytes showing that HIF 1α was the determinant of hypoxia 
induced cell arrest. The levels of HIF 1α correlated with p27 expression, p27 and p21 
transcription and Retinoblastoma protein phosphorylation. This experimental 
evidence paved way for similar studies in human cancer cells.  
HIF 1α was found to play a role in the process of carcinogenesis itself. Hypoxia 
mediated by HIF 1α was shown to mediate angiogenesis, fibrosis and subsequent 
carcinogenesis in hepatic carcinoma (Rosmorduc & Housset, 2010). These actions 
are believed to be mediated through the alteration of platelet derived growth factor 
(PDGF) and VEGF signalling. In 2007, Horree et al studied the role of HIF 1α in 
gynaecological cancers and found it to be an important factor of carcinogenesis. 
They noted the expression of HIF 1α and the proteins influenced by it (Glucose 
transporter-1 protein, Carbonic anhydrase IX and VEGF) in normal endometrium, 
pre-malignant endometrium and endometrial cancer. Their study revealed higher 
levels of HIF 1α and the other proteins as the morphology of the tissues progressed 
from normal to malignancy, with an associated increase in microvessel density 
(MVD). Similar evidence of involvement of HIF 1α pathway in gastric 
carcinogenesis (Griffiths et al, 2005) and breast carcinogenesis (Chen et al, 2010) 
was also discovered. Currently there is no evidence to suggest a similar role for HIF 
1α in oesophageal carcinogenesis. 
In 1999, Zhong et al provided the first clinical data showing the role of HIF 1α in 
human cancer progression. Once the tumour is formed, oncogenes and tumour 
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suppressor genes can modify the HIF 1α regulation and activation, which can be 
modified by the tumour hypoxic levels. HIF 1α expression and function can be 
enhanced by the mutations of tumour suppressor genes, which include p53 and 
pVHL (Maxwell et al, 1999). Birner et al (2001) showed that in patients with 
epithelial ovarian tumours, HIF 1α over expression alone has no impact on the 
prognosis but indicates poor dismal prognosis with non-functional p53. Similarly, 
experimental activation of the P13K or ERK MAPK pathways has shown increased 
recruitment and activation of HIF 1α pathway (Semenza, 2003). This knowledge 
may help in the identification of genetic therapy towards modulating HIF 1α role in 
human cancers. Shi and Fang (2004) also showed HIF 1α as a key factor in 
regulation of VEGF and VEGFR and other angiogenic factors, which are essential 
for tumour survival and spread. It was shown that HER-2 immunoactivity and gene 
amplification, VEGF expression, and Ki-67 expression were correlated strongly with 
HIF 1α expression in lymph node negative invasive breast carcinoma (Bos et al, 
2003). 
There is increasing evidence of the role of HIF 1α in tumour formation, as 
demonstrated by many other experimental studies. Many authors have shown the 
relation between cancer progression and expression of HIF 1α in tumour cells 
implanted into experimental animals. These include hepatocellular carcinoma, 
colorectal tumours, pancreatic, renal cell tumours, gliomas, gastric tumours, prostate, 
breast and melanomas as summarized by Semenza in 2010.  
Telomerase was known to be influencing the cell survival by its action on prolonging 
the telomeres as well as lengthening them. It is essential for tumour proliferation and 
progression and this action of it was targeted in identifying new anti-cancer strategies 
(Newbold, 2002). It was shown very recently that the activation of telomerase and 
subsequent carcinogenic activity was induced through P13 dependent transcriptional 
activation involving HIF 1α as a key transcriptional factor (Heeg et al, 2011). This 
study was done on cell lines of oral-oesophageal cancer and paved way for further 
studies on agents modifying HIF 1α function for anti-cancer effects. 
New evidence is emerging to suggest an important role for HIF 1α in cancer spread. 
Shirato et al (2011) hypothesised that glycosyl transferases and nucleotide sugar 
transporters which modulate glycosylation patterns in the hypoxic environment of 
  _____________________________         Chapter 1     
27 
 
solid tumours are induced by activated HIF 1α.  The glycosylation is an important 
part of tumour spread through metastasis and hence could be influenced by the action 
of HIF 1α. In cancer cells, HIF1α induces overexpression and increased activity of 
several glycolytic protein isoforms that differ from those found in non-malignant 
cells, including transporters (GLUT1, GLUT3) and enzymes (HKI, HKII, PFK-L, 
ALD-A, ALD-C, PGK1, ENO-alpha, PYK-M2, LDH-A, PFKFB-3) (Marin-
Hernandez et al, 2009). These HIF 1α induced isoforms make various tumour cells 
more resistant to physiological inhibitors. 
1.4.1.3.6.2.2 Clinical & prognostic role 
Tumour hypoxia is a feature of rapidly growing solid tumours as they outgrow their 
blood supply and the tumour attempts to overcome this by adapting to the hypoxic 
environment. HIF 1α is a master regulator of this adaptive response and hence is 
integral in the malignant potential of tumours. Activated HIF 1α has been shown to 
target genes required for angiogenesis and survival of tumours in hypoxic 
environments, through of regulation of factors like VEGF and VEGFR (Shi & Fang, 
2004). In addition, HIF 1α overexpression in association with deficiency or mutation 
of tumour suppressor genes such as VHL, p53 and PTEN, and amplification of 
oncogenes (Akt, Ras, ERK1/2) has been frequently seen in human cancer and these 
genetic alterations have been associated with tumour growth, invasion and metastasis 
(Shi & fang, 2004). It has been shown that HER-2 immunoactivity and gene 
amplification, VEGF expression, and Ki-67 expression are correlated strongly with 
HIF 1α positivity in lymph node negative breast carcinoma (Bos et al, 2003). Most 
cancers over-expressing HIF 1α are associated with increased mortality. These 
include breast, stomach, brain, ovarian, endometrial, cervical, prostate and colon 
cancers (Semenza, 2002). In head and neck and non-small cell lung cancers, studies 
have shown conflicting results, probably due to the interaction of HIF 1α with 
apoptotic genes. 
Evidence is accumulating regarding the significance of HIF 1α expression in various 
solid organ cancers. HIF 1α has shown prognostic value in predicting the response of 
oropharyngeal tumours to radiotherapy (Aebersold et al, 2001). Over expression of 
HIF 1α was shown to be marginally associated with poor outcome in non-small cell 
lung cancer (Giatromanolaki et al, 2001). Hung et al (2009) showed that in resectable 
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non-small cell lung cancers, the expression of HIF 1α is related to shorter recurrence 
free and overall survival. They concluded that HIF 1α in association with either 
‘Snail’ or ‘TWIST1’, which are epithelial-mesenchymal transition (EMT) regulators, 
was an independent prognostic marker for recurrence free and overall survival. 
Studies were reported on HIF 1α expression in gastrointestinal tract. HIF 1α 
expression had positive association with tumour size, TNM stage, cellular 
proliferation and micro vessel density/ neo-angiogenesis in pancreatic carcinoma 
(Kitada et al, 2003). Zhang et al showed significantly poorer survival in HIF 1α 
positive pancreatic ductal adenocarcimas, but did not report on its role as 
independent prognostic factor. Over expression of HIF 1α is correlated with poor 
prognosis in gastrointestinal tumour (GIST) of stomach (Takahashi et al, 2003). 
Griffiths et al (2007) studied HIF 1α expression in gastric and gastro-oesophageal 
adenocarcinomas and reported that that expression at invasive edge of the tumour 
was associated with cancer specific survival, lymph node metastases and advanced 
TNM stage. However, HIF 1α did not show any independent prognostic value in 
their study. HIF 1α expression had positive association with tumour size, TNM stage, 
cellular proliferation, micro vessel density/ neo-angiogenesis and prognosis in 
colorectal carcinoma (Kuwai et al, 2003). 
HIF 1α can serve as a prognostic marker for an unfavourable outcome in breast 
cancer patients with T1/T2 tumours and positive axillary lymph nodes (Gruber et al, 
2004). Bos et al’s study (2003) could not show similar results in patients with 
positive axillary lymph nodes: survival only in node negative invasive breast cancer 
patients was independently related to the expression of HIF 1α in their study. 
Generali et al (2006) showed that overall response to therapy and disease free 
survival progressively decreased with increasing tumour HIF 1α and HIF 1α was an 
independent predictor of response. Local recurrence, metastastic recurrence and 
disease free survival after radiation therapy for patients with Stage IIIB squamous 
cell carcinoma of the cervix is predictable with the degree of expression of HIF 1α, 
with high degree of expression demonstrating aggressive tumour (Birner et al, 2001; 
Burri et al, 2003; Ishikawa et al, 2004). HIF 1α protein expression correlated with 
grade, growth pattern, p53 oncoprotein expression, and PCNA index in transitional 
cell carcinoma of the upper renal tract (Nakanishi et al, 2005). Furthermore, a 
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significant correlation was found between HIF 1α protein expression and both 
overall and disease-free survival rates in this study. 
The results in certain cancers are equivocal. Ma et al (2007) showed that HIF 1α 
correlated with MVD and VEGF expression in gastric cancers, which can be used as 
prognostic indicators; Griffiths et al (2005) study has shown improved survival in 
distal gastric cancers with high HIF 1α expression. Two studies do not appear to 
confirm the significant association between HIF 1α over expression and tumour 
aggressiveness or unfavourable prognosis in colorectal cancers (Furlan et al, 2008; 
Kuwai et al, 2003). These results may be due to the ability of HIF 1α to induce 
apoptosis and decrease cellular proliferation in certain morphological types of 
cancers (Griffiths et al, 2005).  
1.4.1.3.6.2.3 HIF 1α in oesophageal cancer 
The role of HIF 1α expression in oesophageal cancer was reported first by 
Koukourakis et al (2001). They studied the role of HIF 1α on the response of early 
oesophageal tumours in 37 patients treated with photodynamic therapy (PDT). PDT 
needs a pre-requisite of cellular normoxia for effective results and their study showed 
that the tumours with higher expression of HIF 1α can be predicted to show less 
response to PDT. But this expression did not translate into effect on survival. Their 
group brought the relation of HIF 1α and oesophageal cancer into limelight, but did 
not report any bench mark for marking the expression of this factor and this makes 
future attempts to repeat their results difficult. They significantly did not mention the 
type of oesophageal cancer (SCC or ACC) in their patient group and also on the 
relation between HIF 1α and other clinicopathological characteristics. 
The potential role of this new molecular factor in the management of oesophageal 
cancer caused interest in the Far East, where the incidence of oesophageal cancer is 
much higher compared to Western population. Kurokawa et al (2003) showed that 
high HIF 1α expression in 130 oesophageal cancer specimens was associated with 
tumour invasion, lymph node metastasis, distant metastasis, pTNM stage, lymphatic 
invasion and worse survival. HIF 1α however did not show independent prognostic 
value in predicting survival. Their group reported that in their patients where in the 
specimens’ margins tested positive for tumour the HIF 1α expression in the tissues 
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was higher. But this is debatable, as positive margins reflect surgical technique rather 
than molecular expressions. 
Sohda et al (2004) first reported a study to identify the role of HIF 1α in predicting 
response to chemoradiotherapy (CRT). They examined 65 biopsy specimens 
endoscopically obtained before administering chemoradiation. Their results failed to 
show any significant relation between HIF 1α expression and the depth of tumour 
invasion, degree of differentiation, TNM staging and 5 year survival. But there was 
complete response to chemoradiotherapy in tumours with low HIF 1α expression 
(13/27) vs. high expression (3/38) and this effect was significantly predictable. They 
concluded that as CRT requires tissue normoxia for optimum results, the HIF 1α can 
act as a surrogate marker to measure levels of tissue oxygenation in oeosphageal 
tumours. They failed to report whether the cancers were SCC or ACC. 
Kimura et al (2004) was the first to explore the relation between HIF 1α and VEGF 
expressions both in vitro and in vivo of SCC of oesophagus. They studied the levels 
of these two factors in oesophageal cancer cell lines in vitro and discovered that their 
levels rise in proportion with degree of hypoxia created. In 82 resected specimens, 
HIF 1α expression correlated with venous invasion, VEGF expression and 
microvessel density. The survival of the patients with high HIF 1α was significantly 
lower than those with low expression, but not as an independent indicator of survival.  
They further published their results on the relation between HIF 1α and p53 (2005). 
They reported that p53 showed over-expression in early cancers implicating its role 
in carcinogenesis, but did not show any association with HIF 1α, VEGF expression, 
angiogenesis or apoptosis. They concluded that factors other than p53 could 
influence HIF 1α activity. Matsuyama et al (2005) detected similar positive relation 
between expression of HIF 1α and VEGF in their series of 215 SCC patients who 
underwent resection, but they too could not show any significant relation between 
HIF 1α and p53 levels in their specimens. They reported poorer disease free survival 
on univariate analysis in patients with high expression of HIF 1α, but no independent 
prognostic potential for HIF 1α and no effect at all on disease free survival. Katsuta 
et al (2005) showed that high HIF 1α expression was associated with lymphatic 
invasion, lymph node metastasis and VEGF expression in their study on 5 
oesophageal SCC cell lines and 48 operated specimens of oesophageal SCC. They 
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believed this was the result of induction of the lymphangiogenic effect of VEGF by 
HIF 1α but they did not study the relationship of HIF 1α on patient survival. Tzao et 
al (2008) studied HIF 1α and VEGF expression in 85 resected SCC specimens and 
reported a concordance of 69.5% between these factors, suggesting at their combined 
role in SCC progression. More significantly this was one of the very few studies 
where independent prognostic value in predicting survival with both HIF 1α and 
VEGF was reported. The only other study which confirmed the role of HIF 1α in 
survival of oesophageal cancer was published recently by Ogane et al (2010). They 
showed that HIF 1α could be employed as an independent prognostic marker, with 
HIF 1α expression reflecting the lymph node involvement, disease free and overall 
survival rates in 96 patients who underwent surgical curative resections in pT1 
tumours. 
Attention has also focussed on the genetic control of HIF 1α and relationship of 
genes to tumour biological behaviour. Matsuyama et al (2005) showed that the level 
of expression of HIF 1α mRNA correlated with HIF 1α protein expression, but with 
no further relation to any clinicopathological factors or survival of the patients. Yu et 
al (2008) showed HIF 1α mRNA expression was higher in SCC cells than normal 
oesophageal cells, and this was significantly associated with lymph node metastasis 
and lymphatic invasion. Similar results were obtained between HIF 1α expression 
and lymph node metastasis & histological grading. Again, survival data was lacking 
in their results. Liu et al (2007) studied the HIF 1α mRNA and HIF 1α levels in 
normal (23), dysplastic (26) and tumour tissues (70) of SCC. The positive expression 
and correlation of both mRNA and HIF 1α increased in carcinoma tissues. While 
they both showed association with tumour depth, metastasis and invasion there was 
no survival data. 
Polymorphisms of the HIF 1α gene were detected in carcinomas of the kidney, 
breast, head & neck, prostate and colorectum. The transcriptional activity of the 
polymorphic gene was found to be higher in hypoxia of prostate cancer (Chau et al, 
2005). Ling et al (2005) tested the HIF 1α gene polymorphism to identify any effect 
this may have on various clinicopathological features of SCC of oesophagus. They 
identified C/T mutations of C1772T gene on a similar level in both test (95) vs. 
control specimens (104). But, C/T expression group compared to others was 
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associated with larger tumours and higher incidence of metastatic lymph nodes. They 
did not identify the relation between the polymorphism and HIF 1α protein 
expression in their study and information on survival was lacking from their results. 
It still remains to be seen if any vital information on the genetic make up HIF 1α 
could be available through further studies, which can have a prognostic potential.  
With the emerging significance of HIF 1α in oesophageal cancer, studies were done 
to identify its role in predicting response to therapy. Wu et al (2007) reported on the 
strength of expression of HIF 1α and survival in patients undergoing chemotherapy 
in SCC. Their study on 48 patients showed that the 2 year survival rate in the group 
with high HIF 1α expression was significantly lower, but they did not further 
evaluate its role as an independent prognostic factor. Hence their results are 
inconclusive. 
Chen et al (2009) studied the relation between HIF 1α expression and Beclin-1, a 
known mediator of autophagy in 54 SCC specimens. There were significantly higher 
survival rates in patients with high Beclin-1 and high Beclin-1/ low HIF 1α 
expression tumours. While the HIF 1α expression was positively correlated with 
differentiation, invasion and clinical stage, it per se did not show significant survival 
advantage. 
Most of the above studies were done on far Eastern populations, reflecting the higher 
occurrence of oesophageal cancer and subsequent interest in this molecule in those 
regions. Limited information is available on the prognostic role of HIF 1α in 
oesophageal carcinoma of western population. Ling et al (2006) published results of 
their study conducted on 53 patients in Germany who underwent neoadjuvant 
chemoradiation followed by curative resection. They showed that HIF 1α mRNA or 
HIF 1α protein expression did not correlate with histomorphological regression or 
survival following treatment, in contrast with many other previously reported studies. 
Griffiths et al (2007a) published their results on the role of HIF 1α expression on a 
combined series of gastro-oesophageal and gastric adenocarcinoma patients, which 
as discussed earlier have different aetiopathological, morphological and biological 
behaviour from the SCC. 
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It is evident that there were no uniform results from the studies reported so far 
regarding the significance of expression of HIF 1α in oesophageal cancer, 
particularly western population. This lacuna in existing scientific evidence prompted 
our current study.  
1.4.1.3.6.3 Detection of HIF 1α 
Immunohistochemistry is an ideal and most commonly employed analytical assay for 
the detection of prognostic markers. The other methods are Western blot technique 
and Enzyme Linked Immunosorbent Assay test (ELISA). 
Immunohistochemistry technique uses an antigen-antibody reaction as the basis for 
the identification or quantification of the factor being studied, originally described by 
Coons et al in 1941. In the initial stages of development of immunohistochemistry, 
Coons introduced a fluorescent molecule conjugated to an antibody to identify the 
antigen – called ‘direct immunoassay’. In indirect immunoassay which he developed 
as a more effective method, the antibody which identifies the antigen is called as 
primary antibody. This antibody is used as an antigen in a different species to 
produce the secondary antibody. The secondary antibody labels the primary antibody 
when introduced into the test and aids in enhancing the signal amplification through 
conjugation. Immunohistochemistry is an established method to identify and quantify 
many molecules in laboratory medicine.    
Monoclonal antibodies were discovered by Köhler & Milstein in 1975. They are 
produced in-vivo as a result of the antibody response induced against a particular 
‘clone’ of antigen producing cells. These reagents are preferably used in various 
antigen-antibody reactions because of the advantages like greatly reduced 
background staining, minimal contamination with other non-specific antibodies and 
consistency between various batches for uniform results. Another feature of the 
monoclonal antibodies is their ability to be used as secondary antibodies for 
advanced Immunohistochemical investigations like indirect assays (Ramos-Vara, 
2005). 
The following are the various methods employed to highlight the antigen-antibody 
reactions during the immunohistochemistry assay for the identification of HIF 1α: 
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Affinity labelling methods: The extremely high affinity of certain non-
immunological substrates is utilised to provide links between the antigen and 
detection agents through secondary antibody. Examples include Avidin-Biotin 
complex and Streptavidin-Biotin complex. Streptavidin-Biotin complex contributes 
to lower background staining (O’Leary & Timothy, 2003). 
Amplification systems: Substrates are added to the assay that generate more targets 
and hence increase the sensitivity of the assay. These substrates utilise all the binding 
sites of the substrates to amplify the signal.  
Detection systems: Various enzymatic and non-enzymatic systems are in use to 
detect the presence of the reporter molecule which identifies the antigen being tested 
(Nakane & Pierce, 1967).   
The Catalyzed Signal Amplification (CSA) System is an extremely sensitive 
immunocytochemical visualisation system based on patented technology (NEN Life 
Science Products, Inc., U.S.). The procedure uses a peroxidase-catalysed deposition 
of biotinyl-tyramide, which in turn is reacted with peroxidase-conjugated 
Streptavidin resulting in a greatly amplified signal (See Figure 5).  
 35 
Figure 5: Catalysed Signal Amplification (CSA) System 
 
 
 
 
Step 1   Step 2    Step 3   Step 4    Step 5 
Application of   Application of   Application of   Application of   Application of peroxidase 
primary antibody. F(ab)2 biotinylated  avidin-biotinylated biotinyl tyramide.  conjugate streptavidin.  
Incubate 15 min  secondary antibody.  peroxidase-complex. Incubate 15 min   Incubate 15 min 
   Incubate 15 min   Incubate 15 min 
 
Legend for Schematics 
            
Primary  Secondary Tissue   HRP  Biotin  Streptavidin  Biotinyl 
Antibody Antibody Antigen  Enzyme Label     Tyramide 
 
(Reproduced with permission from www.dako.co.uk) 
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Western blot method and Reverse Transcriptase – Polymerase Chain Reaction (RT-
PCR) were also used to detect HIF 1α protein and mRNA presence subsequently 
(Wu et al, 2010). More recently molecular probes that detect HIF 1α activity were 
described. One such agent was recombinant protein PTD-ODD-Halo tag (POH) that 
shares the Oxygen dependent regulation pathway as HIF 1α. The POH could be near-
infrared fluorescently labelled and employed to monitor the HIF 1α active regions of 
solid organ cancers in mice (Kuchimaru et al, 2010). This probe showed specific 
affinity to HIF 1α active cells on further Immunohistiochemical analysis and so 
could potentially be used to image hypoxia. Immunohistochemistry was the proven 
method of detecting the presence and strength of expression of HIF 1α. This 
technique was used in various previously reported studies (Gruber et al 2004, 
Ishikawa et al 2004, Kurokawa et al 2003, Schindl et al 2002; Giatromanolaki et al 
2001; Koukourakis M et al 2001).  
CSA technique was used for detecting the expression of HIF 1α in present study. 
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1.5 Oesophagus 
In this section I discussed the aspects of oeosphageal cancer relevant to the 
understanding of the present study. The applied aspects of oesophageal anatomy and 
lymphatic drainage are described, followed by aetiology, clinical features and 
management of the cancer. 
1.5.1 Applied anatomy 
The oesophagus is the continuation of the pharynx for the purpose of carrying food 
into the stomach. It is a muscular tube approximately 26 cm long and 2 cm in 
diameter (Moore et al, 2006). It begins at the level of the C6 vertebra in neck, 
descends anterior to the vertebral column through the mediastinum following a 
generally vertical course, passes through the diaphragm at the level of the T10 
vertebra and ends at the cardiac orifice of the stomach (GOJ) at the level of the T11 
vertebra. 
1.5.1.1 Anatomical divisions 
The oesophagus is broadly divided into cervical, thoracic and abdominal parts. The 
cervical oesophagus measuring nearly 3 – 4 cm extends from the lower border of the 
cricoid cartilage to the thoracic inlet, and ends at approximately 18cm from upper 
incisors. The thoracic part extends from the thoracic inlet to the diaphragmatic 
hiatus, measuring approximately 20cm. The abdominal part extends to only 2 - 3 cm 
below the diaphragm (Alderson, 2000). 
1.5.1.2 Blood supply 
The oesophagus has a rich blood supply through various arteries, which anastomose 
with each other (Hermann & Murugasu, 1966). The cervical oesophagus is supplied 
by the inferior thyroid artery and the thoracic part by the bronchial & oesophageal 
arteries. The abdominal oesophagus is supplied by the ascending branches of left 
phrenic & left gastric arteries. 
The venous return from the oesophagus drains into a peri-oesophageal venous 
plexus. The oesophageal veins from this plexus drain into veins corresponding to the 
arterial supply. 
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1.5.1.3 Lymphatic supply 
The oesophagus has an extensive submucosal lymphatic system that plays a major 
role in the spread of oesophageal carcinoma. The anatomy of the various lymph 
nodes is particularly essential for their removal ‘en block’ during ‘three fields of 
lymphadenectomy’ as advocated by Akiyama (1994). Sobin et al (2002) described 
oesophageal nodes as cervical, intrathoracic and abdominal groups. These 
involvement of these groups of lymph nodes with oesophageal cancer alters the 
staging and subsequent management of the disease.  
1.5.1.4 Histology 
According to standard teaching texts (Kumar et al, 2005), the histology of the 
oesophagus reflects the general structure of gastrointestinal tract except for absence 
of an outer serosa. A cross section of the oesophagus shows mucosa, submucosa, 
muscularis propria and adventitia. 
Mucosa is the innermost layer and is formed by (from inside out) non-keratinising 
stratified squamous epithelium, a non-epithelial layer known as the lamina propria 
and a delicate layer of muscularis mucosa. The submucosa consists of loose 
connective tissue including blood vessels, lymphatics, nerve fibres and submucosal 
glands. The muscularis propria is formed from inner circular and outer longitudinal 
coat of smooth muscle with intervening Auerbach’s myenteric plexus.   
1.5.2 Pathology 
The spectrum of oesophageal disorders is very wide and a review of all the diseases 
is outside this thesis. I discussed only the appropriate conditions and diseases which 
have a role in the aetiology of oesophageal cancer.   
1.5.2.1 Benign conditions 
The benign diseases of the oesophagus can be classified as congenital, inflammatory, 
physiological/ motor and neoplastic. Some of these benign conditions are pre-
malignant and hence these conditions are discussed further here. 
1.5.2.1.1 Congenital 
Congenital cysts - These may be classified into inclusion, retention or developmental 
cysts. Carcinoma arising in these cysts was reported (Olsen et al, 1991). 
  _____________________________         Chapter 1     
39 
 
Diverticula - Outpouchings of the oesophageal wall, usually as a result of intra-
oesophageal pressure. The complications include squamous cell type malignancy 
(Wychulis et al, 1969). 
Mucosal webs and rings - Upper oesophageal (especially post cricoid) web in 
association with iron deficiency anaemia and cheilosis is known as Paterson-Brown-
Kelly or Plummer-Vinson syndrome (Paterson, 1919; Kelly, 1919). This condition is 
a risk factor for postcricoid oesophageal cancer. 
1.5.2.1.2 Inflammatory (Oesophagitis) 
Reflux oesophagitis – The exposure of the lower oesophageal mucosa to the acidic 
contents of the stomach causes inflammation of the mucosa and subsequent chronic 
changes. The causes for this reflux include decreased efficacy of oesophageal 
antireflux mechanism, hiatus hernia, decreased gastric emptying, and decreased 
reparative capacity of oesophageal mucosa or a combination of factors. The clinical 
manifestations are mainly dysphagia and heartburn. Reflux oesophagitis can 
potentially develop in to Barrett’s oesophagus (discussed below under Cancer: 
aetiopathogenesis section) which is a risk factor for oesophageal cancer (Shaheen & 
Ransohoff, 2002). 
Infective oesophagitis: Human Papilloma Virus (Strains 16 and 18) induced 
oesophagitis is believed to play a role in the carcinogenesis (Far et al, 2007) but 
some studies have disputed this causation (Tornesello et al, 2009). 
Chemical oesophagitis – This condition is caused by the ingestion of mucosal 
irritants like alcohol, corrosive acids & alkalis, hot fluids and smoking. The strictures 
caused by lye ingestion can lead to carcinoma in later life (Appelqvist et al 1980). 
1.5.2.1.3 Physiological/ Motor 
Achalasia cardia is a functional disorder of swallowing mechanism due to the 
incomplete relaxation of the lower oesophageal sphincter. This condition can 
increase the risk of oesophageal cancer by 33 times compared to general population 
(Streitz et al, 1995). Zendehdel (2011) recently showed that the incidence of both 
SCC and ACC is substantially higher in male patients with achalasia cardia, but in 
women this is not confirmed. 
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1.5.2.1.4 Neoplastic 
Benign neoplasms of the oesophagus can be classified into gastrointestinal tumours 
(GISTs), true smooth muscle tumours and true Schwann cell tumours (Joensuu & 
Kindblom, 2004). These tumours have varying malignant potential and rarely can 
cause aggressive tumours in oesophagus.  
The common malignant neoplasms (cancer) of the oesophagus are discussed in detail 
below. 
1.5.2.2 Cancer 
The cancers of oesophagus are predominantly epithelial in origin (Bennett, 2009). 
The uncommon types of cancer accounting for <0.1% cases include granular cell 
tumours, basaloid carcinoma, mucoepidermoid carcinoma and endocrine tumours.  
The epithelial cancers are squamous cell carcinoma and adenocarcinoma with 
different spectra of aetiology and morphology but somewhat similar clinical features. 
1.5.2.2.1 Aetiopathogenesis 
The aeatiopathogeneis of the SCC and ACC shows distinct differences. 
1.5.2.2.1.1 Squamous Cell Carcinoma 
Dietary and environmental factors play a major role with a contribution from genetic 
predisposition in the aetiology of SCC.  
Dietary factors are implicated for this cancer in high-incidence regions like China 
and South Africa. They include deficiency of vitamins and trace elements, fungal 
contamination of food and pickled food with high levels of nitrites and nitrosamines 
(Wang et al, 2006). These findings were confirmed on a recent study on Western 
population also. Anantharaman et al (2011) performed Principle Component 
Analysis of dietary and life style factors on incidence of oesophageal cancer. They 
showed meat and nitrate intake was associated with increased risk of both SCC and 
ACC, while alcohol and smoking were associated with SCC. The life style related 
factors like alcohol and tobacco usage are implicated in oesophageal cancer aetiology 
across the world (Morita et al, 2010). These two factors in association can cause a 20 
times increased incidence of SCC (Lee et al, 2005).   
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Genetic factors playing a significant role in the aetiology of SCC were recently 
reported. Mutation of the p53 gene which is a tumour suppressor, disruption of cell-
cycle control in G1phase, activation of oncogenes like EGFR and inactivation of 
tumour suppressor genes have been shown as contributing to development of SCC of 
oesophagus (Mandard et al, 2000). ADH2*1*2, CYP1A1 Val allele and the p53 
codon 72 Pro/Pro genotypes are shown to increase the risk of SCC of oesophagus 
(Hiyama et al, 2007). Common alleles of genes including MTHFR C677T and 
A1298C polymorphisms, the XRCC1 Arg194Trp polymorphisms, the hOGG1 
Ser326Cys polymorphism, and the p53 Arg72Pro polymorphism were shown to be 
moderate risk factors of SCC among Chinese population (Xing et al, 2003). 
1.5.2.2.1.2 Adenocarcinoma 
The majority of cases of ACC arise from Barrett’s mucosa. Barrett’s mucosa occurs 
as a result of chronic exposure of the lower part of oesophagus to gastric juices, 
usually as a result of GORD: up to 5 – 15% patients with GORD show Barrett’s 
mucosa (Shaheen & Richter, 2009). In this condition, the distal oesophageal 
squamous mucosa is replaced by metaplastic columnar epithelium. These metaplastic 
cells have high proliferative activity and in nearly 10% of cases turn severely 
dysplastic or cancerous. The Barrett’s metaplasia increases the risk of oesophageal 
adenocarcinoma by 30 – 125 fold compared to the general population (Wild & 
Hardie, 2003). Anantharaman et al (2011) confirmed this association on principle 
component analysis of dietary and environmental factors in ACC. Recent 
epidemiological review by Kubo et al (2010) showed that that dietary lack of 
vitamins A & C, fibre, fruits and raw vegetables was inversely associated with the 
incidence of Barrett’s oesophagus and ACC.  
Apart from GORD and Barrett’s oesophagus, some isolated genes are known to 
cause increased risk of adenocarcinoma. DNA repair genes like xeroderma 
pigmentosum group D in the nucleotide excision repair pathway and X-ray repair 
cross-complementing gene 1 in the base excision repair pathway can in association 
with each other enhance the risk (Liu G et al, 2007). ALDH2*1*2 and the CYP1A1 
Val allele (Hiyama et al, 2007) are shown to increase the risk of adenocarcinoma of 
oesophagus. Cyclooxygenase-2 gene polymorphisms contribute to the carcinogenesis 
through inflammation and Barrett’s oesophagus (Ferguson et al, 2008). Matrix 
metalloproteinase (MMP) polymorphisms (Bradbury et al, 2009) and MicroRNA 
  _____________________________         Chapter 1     
42 
 
related oncogene mutations (Ye et al, 2008) play a role in the process of cancer 
aetiology. Genetic variants of Caspase-7 and Caspase-9 in the apoptosis pathway 
may also be associated with adenocarcinoma (Liu et al, 2010). 
1.5.2.2.2 Morphology 
1.5.2.2.2.1 Squamous cell carcinoma 
This carcinoma occurs generally in the upper two thirds of the oesophagus. It starts 
as in situ lesion which is confined to the mucosa without evidence of spread, and is 
also known as intraepithelial neoplasm. Teaching texts (Kumar et al, 2005) mention 
four common morphological patterns as the tumour grows in the order of frequency: 
Polypoid, exophytic, ulcerated and diffuse infiltrative types. 
1.5.2.2.2.2 Adenocarcinoma 
This type occurs most frequently at lower end of oesophagus (GOJ). The following 
classification of these tumours is generally followed: 
Type I  Arises from Barrett’s oesophagus and infiltrates GOJ from above 
Type II True carcinoma of the cardia 
Type III Subcardial gastric carcinoma, which infiltrates GOJ from below 
(Siewert & Stein, 1998)  
Multiple foci may appear in an area of ‘field change’ and hence multisite biopsies are 
essential during Barrett’s surveillance programmes (www.bsg.org.uk).   
1.5.2.2.3 Clinical Presentation 
The symptoms of oesophageal cancer are predominantly related to the narrowing of 
the oesophagus by the tumour mass (Devitt et al, 1988). These symptoms are 
dysphagia (difficulty in swallowing, initially for solids followed by liquids), 
odynophagia (painful swallowing), weight loss & debilitation (due to dysphagia & 
general manifestation of cancer) and food bolus obstruction.  Ulceration of the 
tumour may cause haemorrhage, aspiration of food via trachea-oesophageal fistula 
and sepsis.  
Atypical symptoms of oesophageal cancer (Levernment & Milne, 1974) include 
hoarseness due to recurrent laryngeal nerve infiltration by the tumour and palpable 
lymphadenopathy in the neck due to metastatic spread. Concurrent symptoms of 
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GORD and sliding hernia e.g. heartburn, regurgitation and epigastralgia may mask 
the cancer symptoms to some extent, causing delay in diagnosis. 
1.5.3 Management of oesophageal cancer  
The management of oesophageal cancer is evidence based and multidisciplinary. 
Some of the investigations and treatment pathways are debated and I discussed our 
local protocol in this chapter.  
1.5.3.1 Clinical investigations 
Various modes of investigation are available for the diagnosis of oesophageal cancer. 
Each mode has an important role in the diagnostic pathway and many of them also 
significantly contribute to the staging of the disease, as shown below: 
Haematology, Biochemistry: Provides information on the general health and 
nutrition of the patient 
Endoscopy +/- biopsy (Oesophago-gastro-duodenoscopy, Bronchoscopy): Generally 
the first investigation to identify and confirmation of disease, to assess the extent of 
extent of disease 
Peritoneal cytology: Helps in identifying the peritoneal spread of disease (Bryan et 
al, 2001) 
Chest radiograph (CXR): Checks for pulmonary metastases and malignant pleural 
effusion 
Contrast radiology: Provides information on the extent and passability of strictures 
and trachea-oesophageal fistula (Deans & Patterson Brown, 2009)  
Ultrasonography +/- Fine needle aspiration (FNA): Provides imaging of the cervical 
nodal (Bressani et al, 1998) and abdominal visceral metastases; Staging 
Endoscopic Ultrasonography (EUS) +/- FNA: Helps in identifying the extent of 
involvement of the oesophageal wall and regional lymph nodes; staging. Kelly et al 
(2001) have shown that EUS +/- FNA is currently the most accurate modality for the 
‘T’ staging of oesophageal tumours.  
Laparoscopy +/- Ultrasonography: Shows involvement of abdominal viscera and 
peritoneum; Staging (Rau and Hunerbein, 2005) 
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Computed Tomography (CT) and Magnetic Resonance Imaging (MRI): Provide 
imaging for local, regional and distant spread of disease; Staging (Onbas et al, 2006)  
Positron Emission Tomography (PET) +/- CT: Helps in identification of distant 
metastases: Staging (Van Vliet et al, 2008) 
Bone scanning: Helps in identification of skeletal metastases; Staging 
1.5.3.2 Staging of the disease 
Staging of oesophageal cancer prior to treatment is essential for various reasons. As 
all the major modalities of treatment have significant morbidity and risk of mortality, 
staging of the disease helps in choosing the most appropriate form of therapy for 
each individual case. The results of various treatment methods (including clinical 
trials) and results between treatment centres can also be compared using the staging 
system. Final histopathological staging aids in planning adjuvant treatment. Staging 
is one of the most accurate prognostic indicators available, as discussed earlier.  
The various investigative modalities described earlier contribute to the staging of the 
oesophageal cancer as per our local protocol shown below (Figure 6). 
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Figure 6. Preoperative staging protocol at our tertiary oesophago-gastric centre 
(James Cook University Hospital, Middlesbrough) for oesophageal cancer 
History, clinical examination 
     
   Endoscopy & Biopsy 
    
   Diagnosis 
    
   CT Thorax & Abdomen    Palliation 
         
   No metastases   Metastases 
        
   EUS (+/- FNA) & PET-CT   
 
   Resectable   Unresectable 
 
Curative resection (+/- neo-adjuvant treatment) offered if fit 
for surgery 
The clinico-pathological staging is the final summative assessment of pre-operative 
investigations, intra-operative macroscopic findings and postoperative microscopic 
analysis of the resected tissue specimen (Ferguson and Paterson-Brown, 2001). It 
forms the base on which treatment decisions are made. The ‘T, N, M’ staging 
(UICC) is currently the universally accepted standard system for staging of many 
visceral cancers, including oesophageal cancer.  
Tumour (T) staging is assessed by endoscopy (Oesophago-gastro-duodenoscopy/ 
Bronchoscopy), imaging (CT, EUS) and final histology results from the resected 
specimen. Node (N) staging is assessed by various investigative modalities like 
imaging (CT, EUS and laparoscopic ultrasound) and/ or the histology from fine 
needle aspiration (or biopsy) samples. The histology results of the resected lymph 
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nodes following diagnostic laparoscopy or TSO provide a wealth of information, 
which could change the treatment decisions regarding adjuvant treatment. Metastases 
(M) status is also assessed based on imaging (CT, EUS and PET-CT) and in some 
instances histology obtained through EUS-FNA. 
Knowledge about the TNM staging is essential to understand the present study. 
Hence the UICC classification currently used is reproduced here: 
TNM classification 
T – Primary tumour 
 TX  Primary tumour cannot be assessed 
 T0  No evidence of primary tumour 
 Tis Carcinoma in situ 
 T1 Tumour invades lamina propria or submucosa 
 T2 Tumour invades muscularis propria 
 T3 Tumour invades adventitia 
 T4 Tumour invades adjacent structures 
N – Regional Lymph Nodes 
 NX Regional lymphnodes cannot be assessed 
 N0 No Regional lymph node metastasis 
 N1 Regional lymph node metastasis 
M – Distant metastasis 
 MX  Distant metastasis cannot be assessed 
 M0 No distant metastasis 
 M1 Distant metastasis 
  For tumours of the upper thoracic oesophagus 
  M1a Metastasis in cervical lymph nodes 
  M1b Other distant metastasis 
  For tumours of the mid-thoracic oesophagus 
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  M1a Not applicable 
  M1b Non-regional lymph node or other distant metastasis 
  For tumours of the lower thoracic oesophagus 
M1a Metastasis in coeliac lymph nodes 
  M1b Other distant metastasis 
pTNM pathological classification 
The pT, pN and pM categories correspond to the T, N, and M categories. 
Stage 0 Tis  N0  M0   
Stage I  T1  N0  M0 
Stage IIA T2, T3  N0  M0 
Stage IIB T1, T2  N1  M0 
Stage III T3  N1  M0 
  T4  Any N  M0 
Stage IV Any T  Any N  M1  
Stage IVA Any T  Any N  M1a 
Stage IVB Any T  Any N  M1b 
Table: Internationally unified TNM staging grouping of oesophageal cancer  
(UICC: TNM Classification of Malignant tumours, 2002) 
1.5.3.3 Treatment Pathways 
The treatment for oesophageal cancer is increasingly being multi-disciplinary and 
involves the expertise offered by Surgeon, Anaesthetist, Oncologist, Radiologist, 
Pathologist, Dietician, Physiotherapist and specialist nurse team. This is an evidence 
based practice (Stephens et al, 2006) which is followed in all the cancer treatment 
units of UK. In the MDT meeting, the treatment for each patient is considered on an 
individual basis taking into account the patient’s disease stage, fitness, comorbidity, 
nutritional status and response to treatment. MDT has been shown to significantly 
improve the accuracy of staging for oesophageal cancer and enhance the correctness 
of management decisions (Davies et al, 2006).  
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Major advances have been seen in the management of oesophageal cancer in the last 
few decades. The early diagnosis of the disease through education of the general 
population and surveillance of the Barrett’s mucosa patients enabled better results 
though early institution of treatment. Urgent referral of suspected cancer patient to 
specialist centres as per the National Guidelines (www.nice.org.uk) reduced the 
delay before the diagnosis is made. Incorporation of new imaging methods like EUS, 
EUS FNA and PET-CT scan has increased the accuracy of the staging process. 
Improved peri-operative care with optimisation of patient’s pre-operative general and 
nutritional status, thrombo-embolic prophylaxis and newer methods of analgesia 
have resulted in improved outcome from major surgical procedures like TSO. 
Minimally invasive operative techniques like thoracoscopic and laparoscopic assisted 
resections have again improved the patient recovery times and analgesic 
requirements. Availability of less toxic chemotherapy agents and more accurate 
radiotherapy regimens has reduced the side-effects from these modalities. 
The current treatment pathways for oesophageal cancer are summarised as below 
(Figure 7): 
Figure 7. Current treatment pathways at our tertiary oesophago-gastric centre for 
oesophageal cancer 
Diagnosis 
 
Staging 
 
   Early/ locally advanced disease    Metastatic disease 
    
Fitness assessment for surgery  Palliation 
 
 Fit     Unfit 
    
Surgery   Non-surgical modality 
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1.5.3.3.1 Curative care 
Consistent with the principles of cancer treatment elsewhere, potentially curative 
care is offered to patients whose disease staging displays absence of metastatic 
disease. Latest figures show that 36 per cent of patients with SCC were treated with 
curative plan (National Oesophago-gastric cancer Audit, 2010). The potentially 
curative care is discussed as surgical and non-surgical modalities which are offered 
depending on individual characteristics of the disease (Ferguson & Paterson-Brown, 
2001). 
1.5.3.3.1.1. Surgical modality 
As a result of the recent improvements in the multi-disciplinary management of 
oesophageal cancer, the hospital mortality (or death within 30 days post op) has 
improved from 28% in 1950-70’s (Earlam et al, 1980) to 4.5% in this decade (Portale 
et al, 2005). These two reviews have also shown that the overall 5 year survival in 
operated patients has improved from 20% in 1950-70’s to nearly 50% in this decade, 
and supported the surgical modality as the one of the curative treatments for 
oesophageal cancer.  
The principles underlying the oesophageal resection are to remove major part of the 
oesophagus with enbloc lymphadenectomy, so as to achieve tumour free resection 
margins of 10 cm if at all possible (Ferguson and Paterson-Brown, 2001). The gap 
between the two resection margins is channelled using stomach (most common), 
colon or jejunum. Both hand sewn and stapled anastomoses have been described and 
used in various centres. Various techniques are described for resection of oesophagus 
in literature. They include transhiatal oesophagectomy (Turner, 1933), two stage 
oesophegectomy (TSO) (Lewis, 1946 and Tanner, 1949), thoraco-abdominal 
approach (Moore, 1955) and three staged resection (McKeown, 1969) . Thoroscopic 
assisted oesophagectomy was initially described by Gossot et al in 1993. This is a 
relatively advanced minimally invasive procedure which is currently practiced in 
many centres. 
There are various important factors influencing the surgical technique chosen. These 
include location and stage of the tumour, patient’s anatomy and build and surgeon’s 
expertise. The most commonly performed procedure in our institute for tumours in 
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the middle and lower one thirds of oesophagus is two stage sub-total 
oesophagectomy with reconstruction by gastric conduit and a stapled anastomosis.  
1.5.3.3.1.2 Non-surgical modalities 
Radiotherapy and chemotherapy are the primary non-surgical modes of therapy 
which are being offered more frequently with potentially curative aim (Crellin, 
2009). Radiotherapy and chemotherapy have different modes of action and purpose. 
Radiotherapy affects the actively dividing cancer cells at the level of nucleus and is 
more efficient at the periphery of tumour due to direct penetration. This feature of 
radiotherapy aims at improving resectability of the tumour while reducing the impact 
of microscopic residual disease and subsequent loco-regional recurrence. 
Chemotherapy aims at treating the systemic disease in contrast to surgery and 
radiotherapy, while down-staging potentially resectable tumours (Campbell and 
Villaflor, 2010).  
Some patients with resectable disease may not be fit for a major surgery like TSO, 
for whom chemotherapy, radiotherapy or both in combination (CRT) may be 
considered as definitive therapy with the aim of long term disease control (Bartels et 
al, 1998). Definitive CRT was shown as being significantly effective than radiation 
alone (Al-Sarraf et al, 1997) and is being increasingly accepted as standard of care in 
‘inoperable’ but potentially curable oesophageal cancer. Chemotherapy decreases the 
ability of tumour cells to repair radiation mediated DNA damage while acting as 
radiation sensitizer (Lamont & Vokes, 2001). Even among whole patient population 
including ‘fit’ patients, results from definitive CRT rival those of surgery (Chan & 
Wong, 1999), but this modality is still under ‘clinical evaluation’ (National Cancer 
Institute, U.S). In squamous cell carcinoma, a policy of CRT as primary therapy with 
surgery for salvage is suggested (Wilson & Lim, 2000; Tobias & Ball, 2001). This 
strategy provided 46% 5- year survival in squamous cell carcinoma and 68% organ 
preservation in both histological types (Wilson & Lim, 2000).   
The ability of tumour markers to predict which patients will respond to non-surgical 
modality would allow greater certainty in advocating this approach (Crellin, 2009), 
as discussed earlier.  
There is still some role for radical radiotherapy alone in squamous cell carcinoma 
patients with localised disease, who cannot tolerate CRT (Sykes et al, 1998). 
  _____________________________         Chapter 1     
51 
 
1.5.3.3.1.3 Combined modalities 
Treatment of oesophageal cancer is more multi-disciplinary now than ever. This 
stems from the disappointment of the surgeons at loco-regional recurrence as well as 
systemic metastasis in spite of good surgical clearance and even the necessity of 
surgery itself has been questioned in the past (Coia, 1989). The addition of 
chemotherapy, radiotherapy or CRT to the standard surgical practice as adjuvant or 
neoadjuvant therapy is advocated in a significant proportion of cases taking into 
account the individual characteristics of the disease. National Oesophago-gastric 
cancer Audit (2010) showed that 58 per cent of patients who underwent curative 
therapy had surgery with associated chemotherapy as the most common modality of 
treatment.   
Neoadjuvant therapy is offered before the main treatment, to achieve better disease 
control (Crellin, 2009). Adjuvant therapy is the additional treatment given after 
potentially curative therapy, aimed at reducing the risk of recurrence from occult 
disease and hence improving disease free and overall survival. It is offered in cases 
where R0 resection (No macroscopic residual disease left behind) is achieved. 
Evidence for benefit from neoadjuvant radiotherapy is not strong, as Arnott et al 
(1998) showed in their meta-analysis of absolute survival benefit of 4% at 5 years. 
But neoadjuvant chemotherapy in addition to treating occult metastatic disease may 
improve the nutritional status of the patient by tumour shrinkage (Crellin, 2009). 
Many significant trials have confirmed the benefit of neoadjuvant therapies in 
treating oesophageal cancer. Medical Research Council OEO2 trial started in 2000 as 
a RCT with surgery alone arm (400 patients) and neoadjuvant chemotherapy/ surgery 
arm (402 patients) to identify the survival differences if any. The results showed 
significant survival advantage in the latter arm, with 5 year survival figures of 17.1% 
vs. 23% respectively (HR 0.84%, p = 0.03). Similar conclusions were drawn from 
previous trials (Kok et al, 1997; Kelsen et al, 1998) and neoadjuvant chemotherapy is 
currently an accepted clinical practice. The Medical research council Adjuvant 
Gastric Infusional Chemotherapy (MAGIC) trial studied the role of Peri-operative 
regimen with ECF (Epirubicin, Cisplatin and Fluorouracil) in lower oesophageal and 
GOJ adenocarcinomas. This trial concluded in 2006 that this method of treatment 
decreased tumour size and stage, and significantly improved disease free and overall 
survival.  
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Neoadjuvant CRT is currently accepted as a standard of care in many centres (RTOG 
85-01 trial: Cooper et al, 1999). CRT can be given either as sequential or 
synchronous treatment. Both these strategies have shown significant improvement in 
survival in clinical trials: EORTC trial (Bossett et al, 1997) showed significantly 
longer disease free survival in the sequential CRT arm at 3 years but no difference in 
overall survival. Walsh et al (1996) gave synchronous CRT in adenocarcinoma and 
showed overall survival benefit at 3 years. A RCT (Urba et al, 1997) with both 
adenocarcinoma and squamous cell cancers showed an overall survival advantage at 
3 years in CRT arm. CRT also has given better survival than chemotherapy alone 
(Gebski et al, 2007). 
Adjuvant Radiotherapy has a limited role in node-negative patients with residual 
mediastinal disease and did not show statistically significant survival advantage 
(Arnott et al, 2005). Potential drawbacks include morbidity and mortality caused by 
the exposure of the transposed stomach to the radiation, and are to be considered in 
weighing the benefits. Adjuvant Chemotherapy may not be feasible in the immediate 
postoperative period in a good number of cases due to prolonged postoperative phase 
and resultant poor performance status, hence cannot be relied upon. Currently its role 
is limited to patients who had resection for early oesophageal cancer without 
neoadjuvant chemotherapy, but were found to have unexpectedly advanced final 
staging (Crellin, 2009).  
1.5.3.3.2 Palliative care 
The aim of palliative care is to minimise the morbidity associated with the advanced 
disease while maximising the quality of life in the brief period of survival. 
Sometimes this care may prolong the survival by improving the nutrition in patients 
with dysphagia. 
Various factors influence the selection of patients for palliative care. Clear evidence 
of metastatic spread to the lung, liver or bone implies the wide spread nature of the 
cancer, with little hope of cure. Evidence of invasion of adjacent structures like the 
aorta, bronchus or pericardium by cancer determines the inoperability of the primary 
tumour and suggests palliative care. Those patients with potentially resectable 
disease but not fit for either curative surgery or radical radiotherapy due to general 
debilitation and co-morbidities are considered for palliative care. 
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However patient preferences form an integral part of the decision making process. 
MDTs which are a mandatory part of cancer care in UK play an important role in 
making a decision in this aspect, taking into consideration the wishes of the patient 
(Blazeby and Alderson, 2009). 
The methods for palliative treatment fall into three groups. Oncological therapy 
constitutes chemotherapy, radiotherapy or a combination of these two, and is 
currently the most common palliative anti-cancer modality (National Oesophago-
gastric cancer Audit, 2010). The endoscopic/ radiological therapy includes placement 
of stents across the tumour, dilatation of tumour area, thermal ablation and 
brachytherapy. In some frail patients with advanced disease supportive care is 
appropriate. Surgical methods for the palliation of symptoms usually show 
unsatisfactory results and generally non-operative methods are preferred. The 
symptoms that are targeted for palliative relief are: Dysphagia, aero-digestive fistula, 
recurrent laryngeal nerve palsy and chronic bleeding. 
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1.6 Aim of the study 
The aim of this research study was to identify the level of expression of HIF 1α in 
squamous cell carcinoma (SCC) tumour cells of our local population (Teesside, 
Durham, North Yorkshire) and to assess its possible role as a prognostic indicator in 
these patients. The null hypothesis (H0) that there is no relationship between the 
expression level of HIF 1α and survival rates in the recruited patients with SCC of 
oesophagus was to be tested. 
Tumour samples from newly diagnosed patients of SCC of oesophagus were 
prospectively collected and the expression of HIF 1α was assessed in our laboratory. 
The level of expression of HIF 1α was used to stratify the study population into 
separate groups. This expression pattern was correlated to various clinic-pathological 
parameters of the disease (Gender, age, T status, N status, M status, UICC stage, 
tumour differentiation and aim of treatment) to identify any relation. The disease 
related and overall survival of the patients was correlated with the above parameters 
and the HIF 1α expression to identify the factors of prognostic significance in SCC 
of oesophagus. This information could help define the use of HIF 1α in evaluating 
the expected outcome of SCC of oesophagus in our local population.  
This study may possibly influence the management plan and hence the outcome in 
patients with SCC of oesophagus by providing further knowledge on molecular 
prognostic markers. Recommendations on further research into the role of HIF 1α in 
oesophageal cancer could be made based on the findings arising from this study. 
 
  _____________________________         Chapter 2     
 
 
55 
 
 
 
CHAPTER TWO 
 
MATERIALS AND METHODS 
 
 
  _____________________________         Chapter 2     
 
 
56 
2.1 Study design 
The current study was designed as a prospective observational cohort study with 
clinical and laboratory components. 
The clinical component included the identification and recruitment of patients, 
sample collection from them; follow up of these patients and collection of clinical 
data. The laboratory based component comprised the processing of the specimens 
towards the identification of HIF 1α. These were described in the following sections. 
2.1.1 Ethics & Approval 
All the participants in the study were NHS patients. Their safety, dignity and 
wellbeing were assured through the approval within the framework of regulations of 
the NHS and University bodies responsible for Research Governance 
(www.nres.npsa.nhs.uk; www.tees.ac.uk). This study was carried out conforming to 
the ethical principles outlined in the Declaration of Helsinki, 1996.  
The Research Approval Board and the Local Research Ethics Committee of South 
Tees Hospitals NHS Trust granted Research and Ethical approval respectively for 
this project (14 Dec 2004, Appendix 1; 4 Jan 2005, Appendix 2). Subsequently, the 
Ethics Committee of School of Health and Social Care, Teesside University granted 
approval on 8 June 2005 (Appendix 3). 
The Patient Information Sheet (Appendix 4) and the Consent Form (Appendix 5) 
which were prepared as per existing trust research guidelines and submitted to the 
above Boards were used in the project. 
2.1.2 Sample size 
The aim of the current observational study was to identify if the expression of HIF 
1α correlates to the survival of the patients with SCC of oesophagus.  It was felt that 
on an individual patient basis, any change in his or her survival in comparison with a 
similar patient would have significant impact, if determined by HIF 1α expression. 
Hence the effect size could not be defined for this study and a formal power study 
was deemed not possible to determine the sample size. However, available literature 
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was reviewed to identify the sample size in their studies. Five previous studies were 
identified with the sample size in the range of 37 – 54 patients (Koukourakis et al 
(2001), katsuta et al (2005), Wu et al (2007), Ling et al (2006) and Chen et al 
(2010)).  
In consideration of the average number of patients that could possibly be identified in 
the study period, a sample size of 35 - 40 consecutive patients was considered to be 
sufficient to identify with good accuracy the difference in tumour’s biological 
behaviour as reflected in the patient’s survival, with respect to the expression of HIF 
1α. 
2.1.3 Participant selection & Recruitment   
Patients with confirmed diagnosis of oesophageal cancer and/ or under treatment for 
oesophageal cancer at the James Cook University Hospital, Middlesbrough (JCUH) 
during the study period of June 2005 – August 2006 were identified. This 
information was obtained through a prospectively and regularly updated local cancer 
database known as ‘Infoflex’ system (www.infoflex-cims.co.uk). Forty three patients 
were identified satisfying this selection criterion. 
It was felt that it would be unethical to approach patients with very poor general 
condition in addition to the presence of advanced disease for recruitment for present 
study. Hence this was used as an exclusion criterion and accordingly six patients 
were excluded from the study to safeguard their interests. 
The remaining thirty seven patients were contacted and informed about this research 
project in person by the author (P C Munipalle). The approved Patient Information 
Sheet was given to these potential participants and explained to them. Those agreeing 
to participate in the study were recruited by obtaining written consent on the 
approved Consent Form.  
Recruitment of participants was done at the Department of General Surgery, JCUH. 
Areas where contact with the participants in a confidential environment was assured 
were chosen for the purpose of recruitment. The upper gastrointestinal outpatient 
department was a good initial contact point with majority of the participants as this 
was located away from the clinical areas and busy wards, and hence most 
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participants were contacted and recruited here. Some participants were recruited at 
the Endoscopy centre where the patients present for endoscopic procedures. The 
Upper gastrointestinal ward (Ward 23) was allotted for admissions of oesophageal 
cancer patients during operative procedures and part of the recruitment was done 
here. 
2.2 Tissue Collection             
Tissue samples were obtained from the recruited participants either directly during 
endoscopy, or from the operative specimen in those patients who underwent TSO.  
i) During Upper gastrointestinal endoscopy -  
This was a routine investigation in oesophageal cancer patients as discussed in 
section 1.5.3.1 (Clinical investigations). During this procedure, the endoscope was 
introduced through pharynx into the oesophagus and stomach either under local 
anaesthetic spray or conscious sedation (Nagengast 1993, 
www.bsg.org.uk/guidelines). Multiple biopsies in the form of 4 to 6 samples of tissue 
were collected from the macroscopic tumour areas using standard tissue biopsy 
forceps. Tissue biopsies were done during diagnostic as well as therapeutic 
endoscopy procedures like dilatation, stenting and Argon Plasma Coagulation of 
tumour tissue.  
ii) After the operation – The resected specimen containing the distal part of the 
oesophagus harbouring the cancer was sent for histopathological examination as a 
standard practice. Due to the Ivor-Lewis TSO technique, the proximal part of 
stomach was also resected and hence included in the specimen. 
Samples from operative specimens were preferred over endoscopic specimens where 
available. In participants who had both endoscopy and TSO, large amount of sample 
could be obtained from the operative specimens with the possibility of preparing 
multiple slides if need be, in comparison with the specimens obtained through 
endoscopy. Operative specimens could also provide additional source of sample from 
the peri-oesophageal lymph nodes, which could not be sampled through endoscopy. 
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All the endoscopic and operated specimens obtained were labelled with the date of 
collection, details of the patient and site/ or nature of specimen and sent to the 
histopathological laboratory in buffered formaldehyde 10% (v/v) (Genta Medical, 
York, UK).   
The tissues were fixed in the formaldehyde for 24 hours in preparation for further 
processing.  
2.3 Tissue processing & Staining 
The laboratory at JCUH has optimised the protocol for the preparation, processing 
and staining of the tissue samples for assessing the expression of HIF 1α in 
oesophageal SCC tissue. This protocol was validated previously in this laboratory 
conditions (A Ahitan, personal communication) and is described in this section. 
2.3.1 Reagents & Accessories 
The Dako CSA kit (Dako, UK) contained all the following reagents except Reagent 3 
(Table 3). The reagents were prepared as per the suppliers’ instructions: 
Table 3. Reagents in Dako CSA kit 
Reagent 1 Peroxidase Block 
  3% hydrogen peroxide in methanol (v/v) made up of: 
   H2O2 (BDH) 6%, 300 ml 
   Methanol (BDH) 100%, 300 ml 
Reagent 2 Protein Block 
Serum-free protein in Phosphate Buffered Saline (PBS) with 0.015 
mol/L sodium azide 
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Reagent 3 Primary Antibody (Novus Biologicals, UK)  
Mouse monoclonal (HIF 1α 67-sup clone) antibody to HIF 1α (ab463) 
1:1000 concentration (2 l in 2000 l Ventana antibody diluent), 2.90 
mg/ml 
Reagent 4 Link Antibody  
Biotinylated rabbit anti-mouse immunoglobulins in Tris-HCl buffer 
containing stabilising protein and 0.015 mol/L sodium azide 
Reagent 5 Streptavidin-Biotin Complex 
Reagent A – Streptavidin in PBS buffer containing anti-microbial 
agent Bronidox (5 – bromo – 5 – nitro - 1, 3 - dioxane, at 0.1% 
concentration) 
Reagent B – Biotin conjugated to horseradish peroxidase in PBS 
buffer containing anti-microbial agent Bronidox (5 – bromo – 5 – 
nitro - 1, 3 - dioxane, at 0.1% concentration) 
Reagent C – PBS buffer containing stabilising protein and anti-
microbial agent Bronidox (5 – bromo – 5 – nitro - 1, 3 - dioxane, at 
0.1% concentration) 
Reagent 6 Amplification reagent 
Biotinyl tyramide and hydrogen peroxide in PBS containing 
stabilising protein and anti-microbial agent Bronidox (5 – bromo – 5 – 
nitro - 1, 3 - dioxane, at 0.1% concentration)  
Reagent 7 Streptavidin-Peroxidase 
Streptavidin conjugated to horseradish peroxidase in PBS containing 
stabilising protein and anti-microbial agent Bronidox (5 – bromo – 5 – 
nitro - 1, 3 - dioxane, at 0.1% concentration)  
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Reagent 8 Substrate Tablets 
3, 3’-diaminobenzidine tetrahydrochloride (DAB Chromogen) 
packaged with desiccant – 10 mg per tablet 
Reagent 9 Tris-HCl buffer concentrate  
(0.05 mol/L Tris-HCl pH 7.6 containing 0.3mol/L NaCl and 0.1% 
Tween 20 (v/v) 
Reagent 10 0.8% (v/v) Hydrogen Peroxide in water 
Reagent 11 Haematoxylin counter-stain 
The other reagents used in the immunohistochemistry assay for identification of 
 HIF 1α were described below in Table 4 (from Genta Medical, York, UK): 
Table 4. Other reagents used for HIF 1α identification 
Citrate buffer pH 6.0 8.82g sodium citrate (BDH) 
   3 litres of distilled water 
   Adjust to pH 6.0 using N Hydrochloric acid 
N Hydrochloric acid HCl (BDH) 34ml 
   Distilled water 366ml 
EDTA buffer pH 8.0 EDTA (Sigma) 370 mg 
   Distilled water 900 ml 
   Adjust to pH 8.0 using NaOH pellets 
3% (v/v) H2O2 in methanol  
H2O2 (BDH) 30 ml 
   Methanol (BDH) 300 ml 
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Tris buffered saline (TBS; NewEngland Biolabs, Hitchin, Herts, UK)  
   Sodium chloride 8g 
   Tris 0.605g 
   Distilled water 1000ml 
   Adjust to pH 7.6 with N HCl and 0.1 M Tris 
Accessories Target retrieval solution (S1699/ S1700/ K1499) 
5ml calibrated test tubes with cap for use in preparation of 
Streptavidin 
 Substrate container 
 10 ml calibrated test tubes with cap for use in preparation of substrate 
 Forceps 
2.3.2 Technique 
Tissue samples were selected from the endoscopic/ operative specimens by the 
reporting pathologist and the tissue was processed for preservation on a Leica tissue 
processor model TP 1050 (Appendix 6). 
The tissue samples were then embedded in paraffin wax with a melting temperature 
of 56-57°C using a Leica embedding centre model EG 1160. 
Sections were cut at 4µm on a Leica microtome model RM2235 and mounted on 
separate electrostatic slides to increase the adhesion of the sections to the slide. The 
slides were stained with Haematoxylin & Eosin on Shandon varistain gemini 
automated stainer as below: 
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Haematoxylin & Eosin Staining protocol 
Step Reagent Conc. % 
(v/v) 
Time  
(min) 
Agitate 
1 Dry Storage  00:00 None 
2 Heater Station  30:00 None 
3 Xylene  02:00 None 
4 Xylene  02:00 None 
5 Alcohol 100 % 01:00 None 
6 Alcohol 100 % 01:00 None 
7 Alcohol 70 % 01:00 None 
8 Running Water 
Wash 
 01:00 None 
9 Harris 
unacidified 
 05:00 None 
10 Running Water 
Wash 
 01:00 None 
11 Acid Alcohol 0.1% 00:10 None 
12 Running Water 
Wash 
 00:30 None 
13 Bluing Reagent  01:00 None 
14 Running Water 
Wash 
 01:00 None 
15 Alcohol 90 % 01:00 None 
16 Alcoholic Eosin  01:20 None 
17 Alcohol 90% 00:30 None 
18 Alcohol 100 % 01:00 None 
19 Alcohol 100 % 01:00 None 
20 Xylene  01:00 None 
21 Xylene  01:00 None 
22 Xylene  01:00 None 
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The slides showing the following areas were selected for the study: 
 Oesophageal tumour 
 Peri-oesophageal/ peri-gastric Lymph nodes (where available) 
The formaldehyde fixed paraffin processed (FFPP) blocks corresponding to these 
selected slides were retrieved for HIF-1α staining. 
Control material  
To enhance the validity of the laboratory protocol, the experiments were 
controlled through the use of positive and negative controls. The positive control 
is an experiment using a substrate which from previous experience was known to 
produce a positive result in the given uniform experimental conditions. Use of 
such a positive control ensures that the experiment was carried out in the specified 
manner; if the positive control does not produce satisfactory result, the experiment 
is void and repeated. This was useful in eliminating false negative results 
(Johnson & Besselsen, 2002, p204). Representative tissue from a previously 
reported grade 4 renal cell carcinoma (RCC), which was known to express very 
high HIF 1α levels was anonymously selected from archives of Histopathology, 
JCUH and processed as described earlier. One slide of this control material was 
used as positive control for each batch of test slides. 
The negative control is an experiment done in such a way that a negative result is 
produced, to compare against the results from the test. This helps in identifying any 
contamination of the test or presence of any artefacts mimicking the presence of HIF 
1α, hence avoiding false positive results (Johnson & Bessesen, 2002). Both external 
and internal negative controls were employed to ensure the identification of false 
positive results, if any. A slide prepared from the RCC tissue was used as external 
negative control for each batch of slides. One slide of ‘test’ tissue was used as 
internal negative control for each batch of slides. For both these negative controls, 
the application of primary antibody at step 3 was replaced with Tris Buffer Saline 
(TBS). As per the principles of usage of negative control, this control slides shall not 
show any evidence of identification of HIF 1α or similar artefacts. 
  _____________________________         Chapter 2     
 
 
65 
2.3.2.1 Preparation of slides for HIF 1α staining 
For each block selected for the study, two sections were cut at 4µm and floated 
out on a water bath containing distilled water at 50°C. Each section was mounted 
on separate electrostatic slides, which were used to increase adhesion of the 
section to the slide.  Each slide was labelled with an assigned unique identification 
number, which would ensure complete patient anonymity. A suffix number 
relating to tissue type was also recorded on the slide. One of these slides was 
designated as negative control as described earlier. 
The slides were dried in an incubator at 37°C or in a wooden box at room 
temperature until staining started. 
When ready to stain, the prepared slides were placed in metal baskets and heated 
to 60°C for 1 hour prior to immunohistochemical staining. The control slides were 
also treated the same way. It took 5 hours to complete one cycle of staining 
process from these prepared slides. Using the equipment available for the project, 
up to 40 slides including controls could be stained in one cycle. 
2.3.2.2 Processing 
De-paraffinization and rehydration 
The slides were de-paraffinized in 3 changes of xylene (Genta Medical, York, 
UK) for 5 minutes in each solution. This was followed by rehydration of the 
sections with 2 changes of 100% v/v Industrialised Methylated Spirit (IMS) 
(Genta Medical, York, UK) for 5 minutes each, then into 95% v/v and 70% v/v 
strength IMS for 5 minutes each. Finally they were immersed in running tap 
water.  
Antigen retrieval  
During fixation with formalin, the antigenic sites of the tissues would be masked 
by the formation of methylene bridges between various proteins. It was vital to 
unmask these sites for effective binding with antibodies through a process called 
‘antigen retrieval’. The two common methods employed for this task utilize either 
heat or enzymes for the retrieval. The suppliers of the antibodies used in this study 
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(Novus Biologicals, UK) recommended Heat-mediated epitope retrieval (HMER) 
for this purpose. In previous experiments in the JCUH laboratory, the following 
method was validated for providing higher expression of antigen staining in the 
nuclei, with minimal background staining (A Ahitan, personal communication): 
Three litres of citrate buffer at pH6.0 was brought to the boil in a pressure cooker 
(Prestige model 6193, operating pressure 103kPa/15 p.s.i) using a solid sealed hot 
plate (S & J Juniper & Co., UK). Re-hydrated slides placed in metal slide baskets 
were rapidly immersed into this boiling liquid. The lid of the pressure cooker was 
secured and the pressure cooker was continually heated on the hot plate until 
pressure was reached and maintained for a further 6 minutes. 
The pressure cooker was then removed from the hot plate and immersed in a sink 
of cold running tap water to rapidly decrease the pressure. Once pressure had 
reduced, the lid was opened and cold running tap water was flushed inside the 
pressure cooker to replace the citrate buffer. The slides were covered with 
Shandon coverplates and placed in a Shandon sequenza tray (Shandon Sequenza 
Immunostaining Center, Thermoscientific, UK) for further staining. 
2.3.2.3 Immunohistiochemical staining of slides 
The protocol of staining the SCC slides for the identification and quantification of 
the expression of HIF 1α was optimised at the Histopathology laboratory of 
JCUH, based on previous experiments (Ms A Ahitan, personal communication). 
These results have been validated and accepted as appropriate for this laboratory 
conditions. The protocol is described below: 
As a first step, the slides in each Sequenza tray were washed with 3 ml TBS for 5 
minutes.      
The slides were then incubated with Reagent 1 (Peroxidase Block) for 5 minutes, 
followed by a rinse in TBS for 5 minutes. This process was repeated with Reagent 
2 (Protein Block). Each reagent was added at 100l per slide. 
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The slides (except the negative control slides) were then incubated with Reagent 3 
(Primary Antibody) for 60 minutes followed by TBS wash in 3 steps of 5 minutes 
each. Negative control slides were incubated with TBS in place of Primary Antibody. 
This was followed by sequential 15 minute incubations with Reagent 4 (Biotinylated 
Link Antibody), Reagent 5 (Streptavidin-Biotin-Peroxidase Complex), Reagent 6 
(Amplification reagent) and Reagent 7 (Streptavidin-Peroxidase). Each 15 minute 
incubation period was followed by three TBS washes of 5 minutes each.  
Finally, slides were incubated with Reagent 8 (DAB chromogen) for 5 minutes 
followed by a rinse in distilled water. The slides were then counter-stained with 
Haematoxylin as described earlier and rinsed in distilled water (See appendix 7 for 
Staining Protocol Worksheet). 
The slides were mounted and were ready for analysis of the HIF 1α antibody 
expression. 
2.4 HIF 1α Scoring 
HIF 1α antigen was expressed in the cell nucleus as well as cytoplasm as per 
published literature. The suitability of using the expression levels in these two 
different parts of a cell was debatable.  
Hypoxia in a tumour cell results in enhanced expression of HIF 1α and subsequent 
activity only in the nucleus. This nuclear activity in turn mediates the various 
mechanisms of action of HIF 1α throughout the cell. For this reason majority of 
studies on HIF 1α in SCC determined the strength of expression by the extent of 
nuclear staining alone (Kurokawa, 2003; Sohda, 2004; Katsuta, 2005; Matsuyama, 
2005). Similar approach was taken in present study. The HIF 1α expression was 
considered positive if the nucleus stains intensely with the antibody, which results in 
dense brown colouring of the nuclear material.  
Under an Olympus microscope (Olympus Optical, Tokyo, Japan) with × 400 
magnification, concentrated foci of tumour cells were selected in each slide for the 
scoring of expression. The percentage of tumour cells in that field which stain 
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positive for HIF 1α compared to those cells staining negative was scored. Negative 
control slides were also checked to confirm the absence of nuclear staining. 
A scoring system was employed based on previous studies (Schindl et al, 2002; 
Kurokawa et al, 2003). The samples where ≥10% cells showed positive staining were 
scored as ‘High’ expression and the samples with <10% cells with positive staining 
were scored as ‘Low’ expression. This was the common form of scoring system in 
previous studies. Kimura et al (2004) calculated the mean values for the expression 
of HIF 1α and used these to determine the cut-off points between high and low 
expressions – the author’s impression was that this method has intentionally divided 
the whole patient population into similar sized groups. 
The expression of HIF 1α in all the slides was scored independently by author 
(P.C.M.) and a histopathologist (D.S.) without knowledge of clinicopathological data 
on each individual case, conforming to the principles of blind assessment. If there 
was a significant difference in the scoring for a particular case, a mutual agreement 
was reached after a re-reading and discussion.  
The scores were compared for inter-observer validity and the average of the two 
scores was used for analysis of results.  
2.5 Follow up, Data collection & Data Storage: 
Clinical follow-up of the patients was done as per the existing clinical protocol of the 
responsible healthcare teams. This includes the Surgeon, the Oncologist and the 
Gastroenterologist, with the support of the Radiologist and other healthcare 
professionals like Specialist nurses, Physiotherapists, Dieticians and Pain care team. 
The progress of the patient, subsequent tests done and their results etc. were entered 
into the dedicated and secure cancer database called ‘Infoflex’ by data managers as 
per nationally accepted current clinical practice (www.cancerimprovement.nhs.uk). 
In addition, these details were documented in the patients’ case notes. 
The patients’ data were collected from the above resources by the author, which was 
then entered into the project database. The demographic parameters of the 
participants were collected from the case notes. The disease related follow-up 
information was collected from the Infoflex, radiology and histopathology reports.  
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All the data was anonymised with a serial number to denote each participant 
throughout the study and entered in the project database. The security of the data was 
ensured through password enabled secure storage systems.  
2.6 End points of the study 
Survival of the study participants in relation to the expression of HIF 1α was 
considered as primary end point of the study. Survival in relation to various other 
clinic-pathological factors was considered as secondary end point. 
In addition, the relationship between the expression pattern of HIF 1α and other 
clinic-pathological factors was also analysed. 
2.7 Statistics 
Inter-observer variability (measurement of the agreement between the HIF 1α 
expressions scoring of two independent observers) was calculated using Cohen's 
kappa test. Where there was disagreement, both observers repeated the reading of the 
expression and agreed upon a single score. A value of 1 was considered as perfect 
agreement (Cohen J, 1960). 
Correlation between HIF 1α expression in the tumour mucosa and other 
clinicopathological parameters was assessed with 2 test or Fisher’s exact test. These 
were gender, age, T stage, N stage, M stage, integrated UICC TNM tumour stage, 
tumour differentiation, aim of treatment and positivity of resection margins in the 
TSO group. A difference of p<0.05 was considered statistically significant. 
Kaplan Meier curves were used to plot the survival characteristics, which were the 
most commonly employed statistical method for this purpose (Altman, 1991). The 
curves separately represent the survival data of patient groups with high and low HIF 
1α.  For each patient died during the study, his or her death was represented as an 
‘event’ on the curve and the ‘time to event’ of each patient was plotted.  This was 
considered as ‘censored’ data. To identify the difference between two curves with 
censored data, log rank test (also known as Mantel-Cox test) was the appropriate 
method and hence was employed. Disease related and overall survival curves in 
relation to the expression of HIF 1α were constructed using the Kaplan-Meier 
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method. Overall survival curves were plotted in relation to gender, age, T stage, N 
stage, M stage, integrated UICC TNM tumour stage, tumour differentiation and aim 
of treatment. The difference between survival curves was compared with Log Rank 
test. A difference of p<0.05 was considered statistically significant. 
The prognostic value of individual variables was assessed by Cox proportional 
hazards model. A difference of p<0.05 was considered statistically significant. 
SPSS for Windows version 12.0 (SPSS, Chicago, Illinois, USA) was used to process 
the data. 
2.8 Reporting the study 
In order to ensure that the results of observational studies are presented in a scientific 
manner, Strengthening the Reporting of Observational studies in Epidemiology 
group issued guidelines (www. strobe-statement.org, 2007). The results from the 
current study were reported adhering to the principles of the above statement with the 
aid of the check list provided for this purpose. 
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3.1 Patient recruitment pathway 
43 patients with SCC were identified during the study period. Six of them were frail 
with advanced disease stage, and hence they were excluded from the study as per the 
defined exclusion criteria stated earlier (Section 2.1.3). The remaining 37 patients 
were approached for informed consenting, and all of them consented to take part in 
the research. One patient had rethought and retracted from the study citing personal 
reasons, and hence was excluded from the study.  The remaining 36 patients were 
recruited for the study. 
The pathway and the number of patients at each stage of the study are presented 
below as a flow chart (Figure 8), as per the STROBE guidelines (www. strobe-
statement.org, 2007). The HIF 1α score sheet is presented as Appendix 8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Pathway of patient recruitment 
Number of SCC patients 
identified 
43 
Patients suitable for 
recruitment 
37 
Patients excluded as per 
defined criteria 
6 
Patients recruited 
36 
 
Patients opted out 
1 
Successful staining for 
HIF 1α 
36 
 
Low levels of HIF 1α 
17 
High levels of HIF 1α 
19 
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3.2 Expression of HIF 1α in SCC mucosa  
The expression of HIF 1α was found to be predominantly in the cancer tissue rather 
than adjoining normal oesophageal epithelium. Within the cancer cells, the 
expression was found to be concentrated within the nuclei in comparison with the 
cytoplasm as shown below in Figures 9 and 10: 
 
 
Figure 9. Expression of HIF 1α in SCC cells of oesophageal epithelium × 200 
magnification  
*Arrow points to a positively stained nucleus. 
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Figure 10. Expression of HIF 1α in SCC cells of oesophageal epithelium × 400 
magnification  
*Arrow points to a positively stained nucleus. 
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3.3 Expression of HIF 1α in lymph nodes 
Lymph node tissue was available in all the patients who underwent TSO, eight in 
total. The results showing the expression levels of HIF 1α in these lymph nodes (LN) 
are presented below as a flow chart (Figure 11) as per STROBE guidelines. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Pathway of HIF 1α expression identification in lymph nodes of SCC 
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  _____________________________         Chapter 3     
 
 
76 
Four operative specimens yielded regional lymph nodes with metastases, which were 
N1 stage. One specimen contained non-regional metastatic lymph node, which was 
N2 stage. This information is represented in the histogram below (Figure 12): 
 
 
Figure 12. HIF 1α expression pattern in SCC metastatic lymph nodes 
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Study of the expression of HIF 1α in lymph nodes infiltrated with cancer cells also 
showed good nuclear expression as shown in Figure 13. Normal lymph nodes with 
no evidence of cancer cell presence did not show any positive staining for HIF 1α 
expression, similar to normal oesophageal tissues. 
 
 
Figure 13. Expression of HIF 1α in lymph node with SCC metastasis × 200 
magnification 
*Arrow points to a positively stained nucleus. 
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3.4 Inter-observer variability 
The inter-observer variability test showed good agreement between the two 
independent observers regarding the reading of the expression of HIF 1α (Cohen’s 
Kappa 0.82, p<0.01). The score sheet is attached as Appendix 8. 
3.5 Follow up period 
The recruited patients (n = 36) were studied for a period of 1 – 56 months, with a 
median of 42 months. 
3.6 Patient characteristics 
The study population comprised 15 males and 21 females, with a median age of 76 
years (range 52 – 95). 
Out of the 36 patients, 15 were offered treatment with curative intention (TSO for 9, 
one of them after neoadjuvant chemotherapy; Chemoradiotherapy 5; Radical 
radiotherapy 1). 16 patients were offered Palliative treatment (radiotherapy 8, 
chemotherapy 8). 5 patients were offered Supportive care (Figure 14).   
 
         
Figure 14. Aim and mode of treatment pattern 
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3.7 HIF 1α expression and clinico-pathological variables 
The correlation between the HIF 1α expression and various clinico-pathological 
variables is presented below. 
3.7.1 Gender 
Among male patients HIF 1α expression was high in 8 and low in 7 patients; among 
female patients HIF 1α expression was high in 11 and low in 10 patients (Figure 15).  
 
 
Figure 15. HIF 1α and gender 
There was no correlation between the gender of the patient and HIF 1α expression 
(p=0.709). 
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3.7.2 Age 
HIF 1α expression was significantly high (p= 0.022) in patients aged above 70 years 
(13 high: 5 low) and low in patients aged below 70 years (12 low: 6 high) (Figure 
16).   
 
  
Figure 16. HIF 1α and age 
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3.7.3 Tumour (T) stage 
There was no correlation between T stage of the disease and HIF 1α expression 
(p=0.408) (Figure 17). 
 
 
Figure 17. HIF 1α and T stage 
This trend continued whether the T stage was compared to HIF 1α expression in 4 
stages (T1, T2, T3 and T4) or the T stage was categorised into ‘early stage’ (T1 and 
T2) and ‘late stage’ (T3 and T4). 
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3.7.4 Lymph node (N) stage 
There was no correlation between N stage of the disease and HIF 1α expression 
(p=0.846) (Figure 18). 
 
 
Figure 18. HIF 1α and N stage 
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3.7.5 Metastases (M) stage 
In patients with metastatic disease, the expression of HIF 1α was high in 8 patients 
and low in 4 patients. While this is an interesting trend, the difference in rates of 
expression is not statistically significant (p=0.238) (Figure 19). 
 
 
Figure 19. HIF 1α and M stage 
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3.7.6 Integrated UICC TNM stage 
The expression of HIF 1α in the various stages of the disease correlates with the 
stages (p= 0.067) which was nearing statistical significance (Figure 20). 
 
 
Figure 20. HIF 1α and Stage of the disease 
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3.7.7 Margins of the resected specimens 
Eight patients had TSO with curative intent. Of these, 5 specimens had tumour free 
margins which were categorised as proximal, distal and circumferential margins. One 
specimen had positive proximal margin (HIF 1α expression score of 9) and 2 had 
positive circumferential margins (score of 0 and 14). 
  
3.7.8 Tumour differentiation 
No significant trend was observed with the expression of HIF 1α and the 
differentiation of the tumour (p=0.221) (Figure 21). 
 
 
Figure 21. HIF 1α and degree of tumour differentiation 
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3.7.9 Aim of treatment 
Aim of treatment in a way indicates the predicted prognosis of the disease and is 
mentioned as either treatment with a ‘curative’ intent or ‘palliative’ intent. Fifteen 
patients received treatment with curative aim, while the remaining 21 were treated 
either by palliative or supportive care. 
There was no correlation between the expression of HIF 1α and the intended aim of 
treatment (p=0.169) (Figure 22). 
 
 
Figure 22. HIF 1α and aim of treatment 
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3.7.10 Summary 
Summary of the correlation between the above mentioned clinico-pathological 
variables and the expression of HIF 1α in the tumour is summarised below in Table 
5: 
Table 5. HIF 1α and clinico-pathological variables 
Variable P value Total (36) Low expression of 
HIF 1α (17) 
High expression of 
HIF 1α (19) 
 
Gender 0.709    
Male  15 7 8 
Female  21 10 11 
 
Age 0.022*    
< 70 years  18 12 6 
> 70 years  18 5 13 
 
T stage 0.408    
T1  2 2 0 
T2  6 2 4 
T3  16 8 8 
T4  12 5 7 
 
N stage 0.846    
N0  9 4 5 
N1  24 12 12 
N2  3 1 2 
 
M stage 0.238    
M0  24 13 11 
M1  12 4 8 
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Variable P value Total (36) Low expression of 
HIF 1α (17) 
High expression of 
HIF 1α (19) 
 
Integrated UICC 
TNM  stage 
0.067    
Stage I  2 2 0 
Stage IIA  4 0 4 
Stage IIB  1 1 0 
Stage III  17 10 7 
Stage IV  12 4 8 
 
Tumour 
differentiation 
0.221    
Well    
differentiated 
 9 2 7 
Moderately 
differentiated 
 7 4 3 
Poorly 
differentiated 
 20 11 9 
 
Aim of treatment 0.169*    
Curative intent  15 9 6 
Palliative intent  21 8 13 
 
* Fisher’s exact test 
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3.8 HIF 1α expression and survival analysis 
The survival duration of the patients from the time of diagnosis of oesophageal 
cancer to the time of end of study period (or death) is presented below. The relation 
between survival pattern of specific patient groups and HIF 1α expression is 
presented, followed by overall survival pattern and HIF 1α expression. The 
correlation between various other demographical & clinic-pathological parameters 
and overall survival is then presented along with statistical analysis of prognostic 
role of HIF 1α in the study population. 
Persistent disease is the presence of oesophageal cancer in a particular patient from 
the time of diagnosis till the end of follow up period, with no evidence of cure at any 
stage: twenty three patients had persistent disease. Of the remaining 13 patients, who 
were initially cured of the disease as evident on clinical, radiological and endoscopic 
evidence, 8 were diagnosed with recurrence of cancer during follow up and 5 
patients showed no evidence of recurrence till the end of the study period. This 
information is represented in Table 6 below: 
 
Table 6. Status of disease and survival of patients 
Status of the disease at the 
end of study period 
No. of 
patients alive 
No. of patients 
dead 
Total no. of 
patients 
Persistent disease 3 20 23 
Recurrence 3 5 8 
Recurrence free 2 3 5 
 
Further analysis of the survival in the above groups is presented below. 
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3.8.1 Patients with persistent disease (Table 7 and Figure 23) 
Table 7. HIF 1α and survival in patients with persistent disease 
HIF 1α expression No. of patients 
alive (median 
survival in days) 
No. of patients 
dead (median 
survival in days) 
Total no. of 
patients (median 
survival in days) 
High 2 (15%, 813) 11 (85%, 139) 13 (147) 
Low 1 (10%, 1169) 9 (90%, 182) 10 (188) 
Combined 3 (13%, 1011) 20 (87%, 155) 23 (171) 
 
 
 
Figure 23. HIF 1α and survival curve in patients with persistent disease 
The censored data corresponds to the patients who died during the study period. 
There was no statistically significant correlation between the survival rate in patients 
with persistent disease and the strength of expression of HIF 1α (p = 0.457, log rank 
test).
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3.8.2 Patients with recurrent disease (Table 8 and Figure 24) 
Table 8. HIF 1α and survival in patients with recurrent disease 
HIF 1α expression No. of patients 
alive (median 
survival in days) 
No. of patients 
dead (median 
survival in days) 
Total no. of 
patients (median 
survival in days) 
High 2 (40%, 508) 3 (60%, 267) 5 (428) 
Low 1 (33.3%, 239) 2 (66.6%, 298) 3 (239) 
Combined 3 (37.5 %, 428) 5 (62.5 %, 267) 8 (341) 
 
 Figure 24. HIF 1α and survival in patients with recurrent disease  
There was no statistically significant correlation between the survival rate in patients 
with recurrent disease and the strength of expression of HIF 1α (p = 0.216, log rank 
test). 
 
  _____________________________         Chapter 3     
 
 
92 
3.8.3 Patients with recurrence free disease (Table 9 and Figure 25) 
Table 9. HIF 1α and survival in patients with recurrence free disease 
HIF 1α expression No. of patients 
alive (median 
survival in days) 
No. of patients 
dead (median 
survival in days) 
Total no. of 
patients (median 
survival in days) 
High 1 (100%, 1314) 0 1 (1314) 
Low 1 (25%, 1495) 3 (75%, 473) 4 (559) 
Combined 2 (40%, 1404) 3 (60%, 473) 5 (646) 
 
 
Figure 25. HIF 1α and survival curve in patients with recurrence free disease 
There was no statistically significant correlation between the recurrence free survival 
rate and the strength of expression of HIF 1α (p = 0.299, log rank test). 
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3.8.4 Overall survival 
Eight of the 36 patients were alive at the end of the study period spanning 4 years, 
with an overall survival rate of 22%. The overall survival of these 8 patients 
ranged from 252 – 1495 days. The survival of the remaining 28 patients who died 
in this period ranged from 32 – 1700 days. 
The median overall survival for the 36 patients was 232 days after diagnosis. The 
overall survival rate at the end of 1 year (365 days) was 33.3%, 2 years (730 days) 
was 25%, 3 years (1095 days) was 25% and 4 years (1460 days) was 22%. The 
cumulative overall survival curve is presented below (Figure 26):  
 
Figure 26. Overall survival curve in patients with SCC 
The censored data corresponds to the patients who died during the study period. 
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Correlation of overall survival and HIF-1α expression: 
Out of 17 patients showing a low expression of HIF 1α, 14 (82.36 %) died and 3 
(17.64 %) were still alive at the end of study period, with a mean survival of 438 
days and median survival of 238 days. 
Out of 19 patients showing high expression of HIF 1α, 14 patients died (73.68 %) 
and 5 (26.32) were still alive, with a mean survival of 533 days and median 
survival of 196 days (Figure 27). 
 
Figure 27. HIF 1α and overall survival curve 
The censored data corresponds to the patients who died during the study period. 
There was no statistically significant correlation between the overall survival rate 
and the level of expression of HIF 1α (p = 0.908, log rank test).  
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3.8.5 Demographical & clinico-pathological variables and survival analysis 
The correlation between various other demographical & clinic-pathological 
parameters and the overall survival is shown below: 
3.8.5.1 Gender (Figure 28) 
      
 
Figure 28. Gender and overall survival curve 
There was no statistically significant correlation between the gender of the patients 
(M=15, F=21) and the overall survival (p = 0.285, log rank test). 
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3.8.5.2 Age (Figure 29) 
      
 
Figure 29. Age and overall survival curve 
Age of the patient is an important decision maker in treating individuals with 
oesophageal cancer, with 70 years being considered as the age below which there is 
physiological reserve for a patient supportive enough of TSO; hence this age is taken 
as a parameter to evaluate the survival pattern, although not all patients are 
considered for surgery. 
There was no statistically significant correlation between the age of the patients (age 
>70 years = 18, age < 70years = 18) at diagnosis and the overall survival (p = 0.350, 
log rank test).
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3.8.5.3 Depth of tumour invasion (T stage) (Figure 30) 
 
Figure 30. T stage and overall survival curve 
 
There was a trend for better overall survival with early T stage (T1 and T2) disease 
(T1 = 2, T2 = 6, T3 = 16, T4 = 12 patients) but this did not reach statistical 
significance (p= 0.192, log rank test). 
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3.8.5.4 Lymph node (N stage) (Figure 31) 
 
 
Figure 31. N stage and overall survival curve 
 
Again, there was a trend for better overall survival with early N stage disease (N0 = 
9, N1 = 24, N2 = 3 patients), but this did not reach statistical significance (p= 0.171, 
log rank test). 
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3.8.5.5 Metastasis (M stage) (Figure 32) 
 
Figure 32. M stage and overall survival curve 
 
There was significant survival advantage for those with no metastatic disease at the 
time of diagnosis (M0 = 24, M1 = 12 patients; p= 0.05, log rank test).
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3.8.5.6 Integrated UICC TNM stage (Figure 33) 
 
Figure 33. TNM stage and overall survival curve 
 
There was a trend of survival advantage for patients with low stage disease (Early 
stage = 7, Late stage = 29 patients; p= 0.122, log rank test), but this was not 
statistically significant. 
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3.8.5.7 Degree of differentiation of tumour (Figure 34) 
 
Figure 34. Differentiation of tumour and overall survival curve 
 
There was a trend for survival advantage for patients with well differentiated tumour, 
but not at statistically significant level (Well differentiated = 9, moderately 
differentiated = 7, poorly differentiated = 20 patients; p= 0.194, log rank test). 
 
  _____________________________         Chapter 3     
 
 
102 
3.8.5.8 Aim of treatment (curative vs. palliative) (Figure 35) 
 
Figure 35. Aim of treatment and overall survival curve 
 
There was significant survival advantage in patients treated with curative intention 
(Curative intention = 15, palliative intention = 21; p= 0.001, log rank test). 
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3.8.5.9 Multivariate analysis 
On multivariate analysis, treatment aim as curative intent was the only statistically 
significant independent prognostic indicator. 
3.8.5.10 Summary 
The above results are summarised below as Table 10.  
Table 10. Summary of Univariate analysis of factors associated with overall 
survival in patients with SCC of oesophagus: 
Variable Number of patients (36) Median survival (in days) P value 
 
HIF 1α expression   0.908 
Low 17 238  
High 19 196  
 
Gender   0.285 
Male 15 182  
Female 21 272  
 
 
Age (years)   0.350 
< 70 18 240  
> 70 18 176  
 
T stage   0.192 
T1 2 110  
T2 6 242  
T3 16 272  
T4 12 182  
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N stage   0.171 
N0 9 238  
N1 24 197  
N2 3 80  
 
 
Variable Number of patients (36) Median survival (in days) P value 
 
 
M stage   0.051 
M0 24 272  
M1 12 162  
 
Integrated UICC TNM 
stage 
  0.122 
Stage I 2 110  
Stage IIA 4 1700  
Stage IIB 1 240  
Stage III 17 282  
Stage IV 12 162  
 
Tumour differentiation   0.194 
Well differentiated 9 240  
Moderately differentiated 7 147  
Poorly differentiated 20 236  
 
Aim of treatment   0.001 
Curative intent 15 646  
Palliative intent 21 176  
  
 
  _____________________________         Chapter 4     
 
 
105 
 
 
 
CHAPTER FOUR 
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4.1 General discussion 
The present study is the first reported and published one (Munipalle et al, 2011; 
Appendix 9) on the role of HIF 1α in oesophageal squamous cell carcinoma in a UK 
population and second study in European population. Ling et al in 2006 reported the 
only other similar study on SCC of oesophagus in European population, carried out 
in Germany. This study group differs in patient characteristics and possible aetiology 
of the disease from previous studies, which were reported mostly on Asian 
populations (Kurokawa et al, 2003; Kimura et al, 2004; Matsuyama et al, 2005; 
Katsuta et al, 2005; Chen et al, 2009). This is important due to the recently available 
evidence that frequency patterns of HIF 1α polymorphism are different between 
Asian and European populations, as reported by Kim et al (2008) in their study on 
breast cancer. Whether these differences in genetic expression translate into clinical 
behaviour of the tumours is currently not known. 
For staining the tumour tissues, previously validated technique and reagents 
including monoclonal antibodies were used. Our results showed that the strength of 
expression of HIF 1α obtained using this methodology was good and easily 
identifiable. The scoring pattern showed the level of expression of HIF 1α and the 
ratio between high and low expressing tumours to be comparable with previously 
reported studies (Kurokawa et al, 2003; Matsuyama et al, 2005; Katsuta et al, 2005). 
The agreement between the two independent observers (Cohen’s Kappa 0.82, 
p<0.01) regarding the expression of HIF 1α can be rated as excellent to perfect 
according to various statistical authors (Koch & Landis, 1977; Fleiss, 1981). We 
have set the expression level of HIF 1α at 10% as the cut-off mark in our study. If the 
scores of the same sample from the two observers fell on either side of this cut off 
mark, then the results from particular sample were discussed between them to agree 
upon a mutually acceptable average score. The scores of three specimens were 
finalised in this manner. In each instance, the initial scores were found to be close to 
each other, even though falling on either side of the cut-off mark. This confirms that 
the scoring of expression of HIF 1α using similar technique of 
immunohistochemistry is repeatable between different observers.  
The reliability of the laboratory tests was ensured by the inclusion of the control 
material during staining of the test slides. All the RCC specimen slides employed as 
positive controls stained positive during the tests, and hence there were no false 
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negative results. Similarly, all the tests where external and internal negative control 
were provided by TBS stained negative for the expression of HIF 1α, eliminating the 
possibility of false positives. Inclusion of the control material in the protocol had 
ensured good validity and reliability of the staining process. The use of control 
material was not explicitly reported in some of the published studies, and hence the 
occurrence of false positives and false negatives could not be ascertained from their 
reports in contrast to the present study. 
HIF 1α was shown not be expressed in normal oesophageal epithelium, as concluded 
in many previous studies (Koukourakis, 2001; Sohda et al, 2004; Chen et al, 2009). 
The expression of HIF 1α is modulated and up regulated only in the hypoxic cells of 
oesophageal tumour than healthy epithelium, and any valid reason could not be 
justified to repeat similar process again on healthy epithelial cells.  Hence the 
identification of HIF 1α in normal oesophageal epithelium was not included in the 
present study. 
Researchers have reported significant differences in the expression pattern and levels 
of HIF 1α in previous studies on SCC. The reasons for this phenomenon are poorly 
understood. The HIF 1α levels are probably a reflection of the degree of hypoxia in 
the tumour tissue at the time of biopsy. It was shown that the degree of hypoxia 
increases towards the centre of the tumour, to facilitate tumour survival through 
recruitment of anaerobic mechanisms (Busk et al, 2009). Seeber et al (2010) showed 
that in endometrial carcinoma, the expression pattern of HIF 1α can be perinecrotic, 
diffuse or mixed. They postulated that the perinecrotic expression is hypoxia driven, 
while the diffuse pattern is not. So the area in a tumour that is biopsied would 
influence the level of expression of HIF 1α and subsequent identification. It would be 
difficult to standardise the area of biopsy across different studies so that the results 
could be compared.  
In addition, different methods of identifying HIF 1α and scoring its expression were 
employed in various studies as mentioned in chapter 2. This may have resulted in 
different degrees of expression of HIF 1α in the SCC tissues studied. But it might be 
possible to standardise the process of quantifying the HIF 1α expression levels in the 
lines of some previous interesting studies. Ugurel et al in 2001 published the 
reliability of measuring various angiogenic factors namely angiogenin, VEGF, basic 
fibroblast growth factor and interleukin (IL-8) in the serum of 125 malignant 
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melanoma patients in comparison with 30 healthy volunteers. They found their levels 
to be correlating to stage of the disease, and being predictive of overall and 
progression free survival. Literature search failed to yield any such serological 
studies measuring HIF 1α levels in cancer patients. The reason for this could be the 
presence of HIF 1α within the nuclei of the cells, rather than as a serum factor.  
ELISA method could also be employed for quantitative measurement of HIF 1α 
protein in solid cancers, which was not possible with immunohistochemistry alone. 
Formento et al in 2005 identified and validated ELISA technique to quantitatively 
measure HIF 1α levels in in-vitro tumour cell lines. Studies on this promising 
quantitative test may provide a platform to objectively measure HIF 1α expression 
levels in various human cancers without subjective bias. 
Another interesting finding was the ethnicity related variations in the expression of 
HIF 1α. Ribeiro et al (2009) investigated the frequency of C1772T and G1790A 
alleles of HIF 1α gene in four distinct populations from Columbia, Portugal, 
Mozambique and Guinea-Bissau.  They discovered statistically significant 
differences among these populations and suggested a role for this differential 
expression in tumour behaviour and aggressiveness. Currently no information is 
available information on the genetic make-up of HIF 1α among UK population and I 
suggest further studies on the aspect.    
Genetic polymorphism of HIF 1α expression contributing to tumour characteristics 
was suspected for a long time - evidence is now available to support this theory. In 
addition to the study of Ling et al (2005) as described earlier, Shieh et al (2010) 
studied C1772T and G1790A polymorphisms of HIF 1α in oral SCC to identify the 
effect of these on tumour behaviour. They reported a relation between genetic 
polymorphism and the tumour characteristics. Similar polymorphic variations in HIF 
1α genotype were identified in other solid organ cancers like renal cell carcinoma, 
stomach, liver, pancreas, cervix & uterus, breast, colorectal and prostate cancers. 
These findings support further studies on the genetic make-up of HIF 1α to evaluate 
the role of these variations contributing to its function. 
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4.2 Analysis of the results - HIF 1α and clinico-pathological variables 
The patient group had 15 male and 21 female patients, with more preponderance of 
female patients compared with national figures; the male: female ratio with SCC was 
1:0.95 as per the National audit 2010. The HIF 1α expression pattern showed no 
relation to the gender of the patients (p = 0.709). Similar results were showed by 
Kurokawa (2003), Sohda (2004), Katsuta (2005) and more recently Chen (2009). 
Kimura (2004) however reported significantly higher expression of HIF 1α among 
male patients in his series of SCC – 31 male patients out of 72 showed higher 
expression, in contrast to 1 female patient among 10 with higher expression. His 
group had 72 male and 10 female patients though, in contrast to the present study. 
Interestingly the statistics show that the survival rates in oesophageal cancer at the 
end of 5 and 10 years are less in men than women (www.cancerresearchuk.org). 
Possible correlation between the higher expressions of HIF 1α in men and their 
relatively worse survival needs further study. This may alter the management of the 
disease on a gender basis. 
The patient’s age at the time of diagnosis was in the range of 52 – 95 years, with a 
median of 76 years, confirming this as a disease of older adults. The national figures 
show the median age to be 72 years (National audit, 2010). Most of the studies on 
Asian populations that reported patient’s median age quoted this as being the 60’s 
(Kurokawa (2003), Sohda (2004) Matsuyama (2005). This might represent a 
different patient population. To study the role of age on HIF 1α expression, patient 
age of 70 years was taken as the cut-off mark in the present study. The expression of 
HIF 1α in the resulting two groups of patients, namely aged above and below 70 
years was observed. Patient’s age of 70 years was identified as a bench mark because 
during decision making regarding the fitness of a patient for TSO, 70 years was 
traditionally chosen as a limiting factor. Patients aged above 70 years were 
considered to have limited physiological reserve and hence a major operation like 
TSO was not routinely considered above this age due to possible high operative 
morbidity and mortality in this group (Elsayed et al, 2010). This practice may 
influence the outcome of the disease indirectly through the decision making as to the 
intention of treatment. There was significant higher expression in patients aged 
above 70 years (p = 0.022) compared to a younger population but the clinical 
significance of this is currently not known. It is important to identify through the 
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expression of HIF 1α if the characteristics of the disease vary in the elderly, as this 
may influence the current decision making regarding the management of this specific 
age group patients. The present study was the first reported one demonstrating the 
positive relation between the old age of the patient and expression of HIF 1α. 
Kurokawa’s study (2003) showed higher expression in those aged above 60 years, 
but not to a significant level. In contrast, more recently Chen et al (2009) reported 
nearly significant low expression in patients aged above 60 years. The reason for a 
cut off value of 60 years was not supported in either paper. Further studies are 
recommended to evaluate the role of patient’s age on the expression pattern of 
different molecular prognostic markers. If the association of age with the prognosis 
of the patient is more firmly illustrated, this evidence could play a vital role in 
treating the elderly with any stage of oesophageal cancer. To the author’s knowledge, 
there were no reported studies that investigated the relation between patient’s age at 
diagnosis and the survival, independent of the mode of treatment. 
T stage disease pattern showed two patients with T1, six with T2, 16 with T3 and 12 
with T4. Higher numbers of patients in the present study were of a late T stage 
compared with the studies of Kurokawa (2003) and Katsuta (2005). This might be 
due to the well established screening programmes for oesophago-gastric cancer 
detection in the Far East, resulting in identifying the cancer at an early stage. The 
expression of HIF 1α was not significantly different across the four T stages of the 
disease (p = 0.408).  While the T stage was compressed into early (T1 and T2 
together, with 8 patients) and late (T3 and T4 together, with 28 patients) stages, the 
expression pattern was again similar with no difference between these two stages.  
Findings from present study are in agreement with those of Sohda (2004), 
Matsuyama (2005) and Katsuta (2005). In contrast, Kimura (2004) and Chen (2009) 
reported lower expression in early T stage, while Kurokawa (2003) showed higher 
expression with less depth of invasion, similar to the standard early T stage. These 
conflicting results may demonstrate the non-uniformity of expression across different 
patient groups. It is currently not known if the expression pattern of HIF 1α can 
change as the disease progresses from early to late stage. There are practical and 
ethical issues involved in studying the progression of the disease on the expression 
pattern of HIF 1α though – in patients with treatable disease which responds well to 
treatment, it is not possible to study the progression. In patients with advanced 
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disease at the time of presentation, not much information could be gained by the 
follow up of the disease, and it might be unethical to subject them to further tests 
which are not likely to benefit them personally. 
Tumour differentiation is considered as one of the indicators of inherent tumour 
aggressiveness with well differentiated tumours generally showing good prognosis. 
While majority of patients in the present study had poorly differentiated tumours (20 
out of 36), the expression pattern of HIF 1α did not differ significantly across the 
groups (p = 0.221). Chen et al (2009) reported significantly higher expression as the 
tumour differentiation gets poorer. 
The expression pattern was not influenced by lymph nodal status either. 24 patients 
had N1 status, followed by 9 patients with no lymph nodal involvement (N0) and 3 
patients with N2 status. No significant differences were observed among these 
groups (p = 0.846), similar to the reporting of Sohda and Matsuyama.  There were 
conflicting results from other studies. Katsuta and Chen described much higher 
expression in tumours with lymph nodal metastases, in contrast with Kurokawa who 
did not. One possible answer for these contrasting results could be explained by 
genetic polymorphism, which was the presence of genetic structure in different forms 
within the same species. It was observed that SCC tumours with certain HIF 
genotypes (C/T) were associated with higher lymph node metastases and this might 
be the reasons for the different results in the studies so far (Ling et al, 2005). He 
studied the single nucleotide polymorphism (C1772T) in HIF 1α gene and reported 
that genotype C/T was found to be associated with larger tumours and more frequent 
occurrence of lymphatic metastases. 
Analysis of expression of HIF 1α as per the metastases stage (M) showed that there 
was difference between the two groups. Eight out of 12 primary tumours which 
metastasised showed higher expression, compared to 12 out of 24 primary tumours 
which were locoregionally confined. This may represent the inherent nature of some 
tumours to adapt to hypoxic environment better and hence spread beyond the 
primary tumour. The different levels of expression did not reach statistical 
significance though (p = 0.238), in agreement with Sohda. Again, Kurokawa reported 
that tumours with no evidence of metastatic spread showed significantly higher 
expression of HIF 1α in contrast to us. These finding show the inconsistencies in the 
expression of HIF 1α pertaining to various tumour characteristics. The presence of 
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occult metastases and micrometastases at the time of initial diagnosis is one of the 
main reasons for so called ‘tumour recurrence’ and the current diagnostic techniques 
are insufficiently powered to detect the presence of these. If HIF 1α expression could 
help identify the tumours which are likely to metastasise, patients with such primary 
tumours could be treated more aggressively with systemic therapies so as to 
minimise potential spread. Multicentre retrospective studies looking at the metastatic 
status of a large number of patients with SCC and the HIF 1α expression levels in the 
primary tumour may provide answers for this. 
However, there was marked higher expression of HIF 1α in integrated TNM stage IV 
tumours compared to stage III, nearly reaching statistical significance (p = 0.067). 
This may again represent the trend of higher expression in more advanced or more 
aggressive tumours. Chen also reported similar pattern. It is not known at this stage if 
the expression pattern gets more prominent as the tumour advances, or the tumour 
advances due to the higher expression. The results from present study differed from 
previous studies of Kurokawa et al (2003), who showed significantly higher 
expression in early p (pathological) stage disease. 
The aim of the treatment showed only a trend of difference in the pattern of 
expression of HIF 1α in the present study (p = 0.169). The aim of treatment for a 
cancer patient is described as with either curative intent or palliative intent, 
depending upon various disease and patient specific factors. Fifteen patients received 
treatment with curative intent while 21 were treated palliatively. It is interesting that 
HIF 1α expression was higher though not significantly in the group of patients 
treated with palliative intent, which may reflect the advanced nature of the disease 
and hence expected poorer prognosis.  
The present study could not show statistically meaningful results concerning the 
expression levels of HIF 1α with two variables. One of them was the comparison of 
the expression levels of HIF 1α in lymph nodes with metastatic spread. Five 
operative specimens showed the involvement of metastatic lymph nodes all of which 
expressed HIF 1α, with one N1 node and one N2 node demonstrating high 
expression. Three N1 nodes lymph nodal specimens showed low levels of 
expression. Due to the small number of the specimens tested the results were 
insufficient for any statistical analysis.  
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We had similar results with resection margins of the tumour specimen. As the 
resected oesophageal specimen can be described as ‘tubular’, it has proximal, 
circumferential and distal margins. Presence of tumour in the resection margins 
represents the likelihood of residual tumour and subsequent high chances of local 
recurrence, and hence this parameter was included in the data. The National Audit 
2010 reported that among 1907 patients who underwent TSO, the percentage of 
specimens where in the longitudinal and circumferential resection margins showed 
tumour presence was 6.4% and 29% respectively. In the present series, out of eight 
specimens from the patients who underwent TSO, one showed positive proximal 
margin and two showed positive circumferential margins on a similar trend. Two out 
of these three specimens showed high expression levels of HIF 1α while the other 
one showed low expression. Kurokawa analysed the expression pattern with relation 
to surgical margin among 130 SCC specimens and reported low expression in 6 out 
of 9 positive margins. While the involvement of the margins reflects more of a 
surgical technique, the tumour size also influences this which in turn is dependent on 
the inherent tumour biology.  
Evaluating the expression of HIF 1α pertaining to lymphatic and vascular invasion 
by the tumour cells could be considered if more resected specimens were available. It 
is interesting to see that many previous studies (Kurokawa et al, 2003; Kimura et al, 
2004; Katsuta et al, 2005) showed higher expression of HIF 1α associated with 
lymphatic invasion by tumour cells. Venous invasion also was reported to be 
associated with higher expression (Kimura et al). 
The relation of HIF 1α expression with clinico-pathological variables was 
summarised in Table 5 (Chapter 3). Statistically significant higher expression was 
noticed in primary tumours of patients aged above 70 years. Only a trend of higher 
expression was noticed in tumours with stage IV disease compared to stage III 
disease, and in tumours treated with the aim of curative intent. 
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4.3 Analysis of results - HIF 1α and Survival (primary end point) 
The recruited patients were followed up for a period ranging from 32 – 1700 days (1 
- 56 months), with a median of 42 months. Five year study period was traditionally 
employed to identify the mortality figures from cancers studies and the present study 
nearly approached it, with the longest follow up being 4 year 8 months. The survival 
was reported as disease specific and overall survival.  
Disease status during the study period separated the patient population into different 
groups with independent survival characteristics. 23 patients had persistent disease 
since the time of diagnosis with no evidence of cure (group A), while 8 had 
recurrence (group B) and 5 patients achieved complete cure with no evidence of 
recurrence (group C). From each of these groups respectively, 3, 3 and 2 patients 
were alive by the end of the study period. In group A, 13 showed high and 10 
showed low expressions HIF 1α. There was no statistically significant difference in 
the survival pattern of patients with high and low expression and hence not related to 
the expression of HIF 1α (p = 0.457). In group B, five patients showed high and the 
rest low expressions of HIF 1α. Their survival pattern again was not different (p = 
0.216). In group C, one patient showed high expression and the rest low expressions 
of HIF 1α. Again, the difference in the survival of this group was not statistically 
significant and independent of HIF 1α expression (p = 0.299). 
The overall survival takes into consideration only the survival of the patient, 
irrespective of whether the death was caused by the cancer or any other unrelated 
causes. In many patients it was not possible to ascertain the actual cause of death. 
Overall survival is generally reported as the percentage of the patient population 
alive at a particular time since diagnosis. The overall survival rate in the study 
participant population at the end of one year from the time of diagnosis was 33.3%, 2 
years was 25%, 3 years was 25% and 4 years was 22%. These rates were comparable 
with the hitherto reported UK survival figures (www.cancerresearchuk.org). 
Recently published results from the National Oesophago-gastric Cancer Audit 2010 
show 2 year survival figures of 55% for patients treated with curative intent and 12% 
for those treated palliative. The present study comprised a mixed patient population 
with higher number of palliative group (23) compared to 13 patients in the curative 
intent group; so results were comparable to national figures. 
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Expression of HIF 1α showed a trend of influence on the overall survival of SCC 
patients in the present study. The median survival in the 17 patients with low 
expression of HIF 1α was 238 days, in comparison with 196 days in the 19 patients 
with high expression. However this difference was not statistically significant. The 
significance of the sample size in the present study might have influenced this result. 
For example, it was well established that ‘T’ and ‘N’ stages have a prognostic 
significance but this was not observed in our study likely due to small sample size. A 
bigger sample size could have possibly confirmed the role of these stages on 
survival. On similar lines, the role of HIF 1α could have been more clearly observed 
with a bigger sample size. 
Our results were in agreement with many previous studies, which reported various 
levels of correlation between HIF 1α and survival. Koukourakis (2001), Kimura 
(2004), Katsuta (2005) and Chen (2009) showed a trend of poorer overall survival in 
patients with higher expression of HIF 1α but not at statistically significant level; 
Kurokawa (2003) reported significant poorer overall survival in patients with higher 
expression, but not as an independent prognostic indicator; Matsuyama (2005) 
reported statistically significant worse disease free survival associated with higher 
expression, but again not as an independent indicator.  
Ling et al (2006) showed that HIF 1α mRNA or protein expression did not correlate 
with histomorphological regression or survival following neoadjuvant chemotherapy 
for SCC. Kimura (2004) eliminated the effect of neoadjuvant chemotherapy on 
survival by looking at the results of patients who were not given this treatment, and 
reported a contrasting significant survival advantage in the group with low HIF 1α 
expression. 
Ogane (2010) published the only available direct evidence linking HIF 1α expression 
to prognosis in SCC. His group studied 96 operated specimens with pT1 disease and 
showed that HIF 1α expression was positively correlated to lymph node metastases. 
Moreover, both disease free and overall survival irrespective of the lymph node 
status were influenced by HIF 1α expression, with higher expression predicting 
poorer survival. However, all the patients had disease confined to T1 stage in their 
study, which is to be taken note of. His results could not be applied across the 
spectrum of pT disease stages, while many other studies included patients with all pT 
stage patients in their studies. Majority of the patients with T1 disease would be 
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treated with curative aim anyway and hence the need to identify a better prognostic 
indicator is more vital with more advanced disease. Many studies including the 
present one have included all the T stages of the disease for this reason (Koukourakis 
(2001), Kurokawa (2003), Kimura (2004), Katsuta (2005) and Chen (2009)). 
The effect of HIF 1α expression on survival probably depends on the interplay 
between inherent malignant potential of the tumour and the balance between 
apoptotic and anti-apoptotic genes. Sowter et al (2001) demonstrated that the 
presence of cell death genes like Bcl2/adenovirus EIB 19kD-interacting protein 3 
(BNIP3) and its analogue Nip3-like protein X were amplified in the perinecrotic 
areas of tumour by the presence of HIF 1α. This action of HIF 1α is in contrast to its 
other effects like escalating anaerobic metabolism. At the same time, the up-
regulation of apoptotic factors like p53 is independent of HIF 1α regulation (Wenger 
et al, 1998). Hence, it is currently believed that there are a multitude of hypoxia 
responsive factors balancing the tumour survival and it is this interplay that 
determines a solid tumour’s behaviour and survival pattern. 
4.4 Analysis of results - Other clinico-pathological variables and survival 
(secondary end points) 
The overall survival pattern in relation to various clinic-pathological variables was 
analysed. The overall survival was independent of the gender (p = 0.285) and age (p 
= 0.350) of the patients in the study. The trend of improved overall survival were 
noted in patients with initial T stages (T1 and T2; p = 0.192), negative or early nodal 
stages (N0 and N1; p = 0.171), and early stages of integrated TNM (I, IIA and IIB; p 
= 0.122) but these trends did not reach levels of statistical significance. Similar result 
was noticed with well-differentiated tumours (p = 0.194).  
We however recognised two independent variables with significant impact on overall 
survival, namely status of metastases (M) and aim of treatment. M status showed 
significant prognostic value in determining the survival pattern of the patients in the 
study. Patients with no evidence of metastases at the time of diagnosis showed 
significant survival advantage compared to those with metastases at the time of 
primary diagnosis. The absence of detectable metastatic disease confirms that the 
disease is confined to loco-regional stage at the time of diagnosis; this might 
represent either earlier detection of the disease or better biological behaviour by the 
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tumour. This would explain the better survival rate in this group of patients. But the 
M status failed to show significance as an independent prognostic indicator. 
Similarly, patients treated with curative aim had significantly better survival rates 
than those treated with palliative aim. Opting for treatment with curative aim implies 
favourable factors – that the tumour was in early stage, and the patient has good 
performance status and could tolerate the treatment. It was expected that the 
combined effects of these factors was likely to produce the better survival rates in 
that sub-group of patients. In fact, only the aim of treatment was the independent 
prognostic factor on multivariate analysis of the study results.  
The survival analysis was summarised in Table 10 (Chapter 3). No difference 
correlating with the expression of HIF 1α was noticed with the disease specific 
survival; a trend of better overall survival was noticed in the low expression group 
but again this difference was not statistically significant (p > 0.05, log rank test). HIF 
1α was not an independent prognostic factor for survival (p> 0.05). Absence of 
metastases at diagnosis (p = 0.05) and treatment with curative intent (p = 0.001) were 
statistically significant prognostic factors on univariate analysis; on multivariate 
analysis, treatment with curative intent was the only independent statistically 
significant prognostic factor (p < 0.001). 
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4.5 Limitations of present study 
The present study had some limitations which affected the usefulness of the results. 
These are discussed below.  
4.5.1 Sample size 
The study results could have been more robust if a larger number of patients were 
available for the study. Even though all the eligible patients during the study period 
were considered for recruitment, due to the limited number of the patients affected 
by SCC the numbers were confined to 43. The general condition of some patients 
further limited the study population. Six patients were frail and their disease was 
advanced by the time of identification of their disease. This led to their exclusion 
from the study. As many of the SCC patients are elderly, this fact has to be 
considered in considering sample size on similar population in future. 
A longer recruitment period would have increased the sample size. Due to limited 
resources available the current study was confined to the present numbers.   
4.5.2 Non-consideration of adenocarcinoma 
The present study did not include the identification of expression of HIF 1α in ACC 
of oesophagus as part of the current project. The methodology that was used in the 
study was based on previous experiments done in JCUH laboratory, to identify the 
feasibility of scoring the expression of HIF 1α using the Mouse monoclonal (HIF 1α 
67-sup clone) antibody to HIF 1α (ab463, Novus Biologicals, UK). These initial 
experiments showed satisfactory levels of expression of HIF 1α in SCC tumour cells, 
but not in ACC. Out of eleven SCC tumours, only one did not show any expression 
of HIF 1α while 23 out of 28 ACC tumours failed to show any expression (Ms A 
Ahitan, JCUH, personal communication); In the five specimens, the expression was 
faint and could not be utilized for the identification of expression levels. Hence the 
assessment of HIF 1α in ACC using the tested methodology was considered 
unreliable and accordingly the ACC patients were not included in the study group. 
Takala et al (2010) also reported very high occurrence of HIF 1α in SCC than ACC 
of oesophagus (p=0.009). Various other authors studied the expression only in SCC 
of oesophagus, but did not explicitly mention the reasons for not including 
adenocarcinoma (Kimura, Katsuta, Yu). 
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The reasons for the failure of satisfactory assessment of HIF 1α expression in ACC 
of oesophagus were not totally understood. This might be due to the differences in 
the molecular pathways or the hypoxic environments in these two distinctly different 
tumours. The reagents and antibodies used to identify the expression itself might be a 
cause for the lack of expression. It is interesting to note that so far only one centre 
has reported on the satisfactory expression of HIF 1α in oesophageal ACC. 
Expression of HIF 1α and other hypoxia inducible proteins in gastric and gastro-
oesophageal adenocarcinoma was reported by Griffiths et al in 2007. His team used a 
different antibody (610958, BD Biosciences) and these results were published after 
out laboratory work was completed. Hence similar methodology could not be 
employed for the present study.  
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The methodology employed for the present study was valid and reliable. The results 
suggested no statistically significant role for HIF 1α expression in influencing 
survival of SCC patients within the limitations of the study. Hence the null 
hypothesis that there is no relationship between the expression level of HIF 1α and 
survival rates in the recruited patients with SCC of oesophagus is accepted. 
HIF 1α expression was higher in patients aged above 70 years but the significance of 
this is currently unknown. Better overall survival was observed in patients treated 
with curative intent and with no evidence of metastatic spread at the time of 
diagnosis, with only the aim of treatment being the independent prognostic indicator. 
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The present study identified certain areas where further research would be beneficial 
in extending the current knowledge about the role of HIF in human cancers, and 
oesophageal cancer in particular. HIF 1α is gaining more attention due to the 
availability of drugs which can influence the cancer biology by inhibiting HIF 1α 
(Semenza, 2010). A variety of anti-cancer therapies could be potentially developed 
by studying the role of HIF 1α further. I would recommend the following works to 
facilitate development of these areas. 
A multicentre research project is recommended to further study the expression levels 
of HIF 1α in oesophageal cancer tissues. Such a project would recruit a larger patient 
population and a retrospective design would further expand the available tissue 
sample size. The statistical validity of the information obtained pertaining to HIF 1α 
expression and various clinicopathological parameters would be further enhanced. 
This knowledge would assist in answering the question about whether further 
research is needed into the role of HIF 1α in SCC of oesophagus. 
Another vital area for further attention is the increasing incidence of oesophageal 
ACC throughout the Western world and majority of the newly diagnosed 
oesophageal cancers are ACC in nature. Currently the incidence of distal 
oesophageal and gastro-oesophageal junctional ACC is increasing faster than any 
other malignancy in the Western world (Blot et al, 1991; Demeester, 2006). The 
prognostic role of HIF 1α in ACC needs to be evaluated further in view of the 
significant impact it may have on public health. HIF 1α was detected in 
adenocarcinomas of various organs in other studies. These include Griffiths et al 
(2007, gastric & GOJ); Wu et al (2010, colorectal); Jung et al (2011, prostate), Wang 
et al (2011, pancreas), Gu et al (2010, lung), Aprahamian (2010, liver), Espinosa 
(2010, endometrium), Iwashita (2010, renal cell carcinomas) etc. These studies used 
different methods and reagents for this purpose. Their methods and reagents could be 
utilised to identify the best methodology to study HIF 1α expression and its clinical 
relevance in oesophageal ACC.  
Obesity, gastro-oesophageal reflux and Barrett’s metaplasia were identified to be the 
major risk factors to ACC of oesophagus (Vial et al, 2010; Wang et al, 2011). Hence 
it is vital to study further the role of HIF 1α in the aetiology of Barrett’s dysplasia-
ACC sequence as this might have huge implications in the management of the 
oesophageal cancer. Studies on the role of HIF 1α expression in the adenocarcinoma 
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sequence are recommended to be carried out on the local population to develop 
knowledge in this area. 
The tissue sampling and scoring methods to evaluate the expression of HIF 1α could 
be standardised. This would assist in comparing the results from different studies and 
in providing a platform for meta-analysis. Automated methods are available for 
quantitative identification in immunohistochemistry and trials are recommended to 
study the utility of these techniques in measuring HIF 1α expression. This could help 
in easy processing of a large quantity of sample material while reducing the observer 
associated bias.  
Age of the patient which was found to show interesting relation with the survival of 
the patient deserves to be studied further. Similarly, further research into the 
association between patient’s age and various molecular prognostic indicators is 
recommended. This knowledge may influence the treatment options which currently 
consider patient’s age as a factor in choosing them. 
The possible role of HIF 1α polymorphisms in tumour behaviour and in causing 
differences in disease characteristics across different ethnic populations needs further 
study. This might help in targeting specific forms of HIF 1α which are responsible to 
cancer in a given population. The genetic make-up of HIF 1α within the UK 
population also needs further research. 
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Appendix 4 – Patient Information Sheet 
 
PATIENT INFORMATION SHEET 
(For patients being treated for cancer of the oesophagus) 
 
(Version 2: 6 Dec 2004) 
 
‘Expression of Hypoxia Induced Factor 1 alpha as a prognostic 
indicator of long time survival in oesophageal cancer’ 
 
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it 
will involve. Please take time to read the following information carefully and 
discuss it with others if you wish. Ask us if there is anything that is not clear 
or if you would like more information. Take time to decide whether or not you 
wish to take part. 
 
Thank you for reading this. 
 
1. What is the purpose of the study? 
 
Research is an important part of medical practice. Many treatments, 
operations and medicines which are life saving throughout the world were 
discovered through research, including most of the currently used treatments. 
Research is an ongoing process and aims at constantly improvising the 
patient care. 
 
We are trying to find out if some of the chemical substances associated with 
cancer tissue tell us about the future course of the disease. This information 
may help us in knowing beforehand about the prognosis of a particular 
patient. In long run this information might be utilised to find more effective 
treatments for cancer. 
 
2. Why have I been chosen? 
 
As you are aware you are being treated for cancer of your gullet. We 
appreciate your help on carrying out research on the tissue samples removed 
from your gullet. 
Other patients with similar disease and undergoing treatment will also be 
approached and requested for participation in this study. 
 
3. Do I have to take part? 
 
It is up to you to decide whether or not to take part. If you decide to take part 
you will be given this information sheet to keep and be asked to sign a 
consent form. If you decide to take part you are still free to withdraw at any 
time and without giving a reason. A decision to withdraw at any time, or a 
decision not to take part, will not affect the standard of care you receive.    
 
 
                                                                     ______________________________ Appendices 
 
 
164 
 
 
4. What will happen to me if I take part? 
 
After any camera test or surgery the removed tumour tissue and normal 
tissue will be routinely sent for laboratory examination to know the stage of 
the cancer and to decide if you need any further treatment. We would like to 
subject a sample of these tissues for a special test as part of our research. 
During this test a special stain is used to detect the level of the above 
mentioned chemical in the tissues. In previously done studies the level of this 
chemical has been found to be representing the severity of some other 
cancers and we would like to know through this study if it happens in gullet 
cancer too. 
 
This project involves you no more that another patient undergoing the same 
operation but not participating in research as we are only looking at the 
tissue, which is removed as part of your operation. That means your hospital 
stay, medication, investigations or future follow up with us/ your GP is not 
altered in any manner. 
 
We would like to keep you under this study as long as possible with your 
permission. As we treat you for the cancer we will collect information about 
the progress and response of the disease.  This information is used in this 
study. 
 
At present we do not have sufficient information based on which your 
treatment may be changed and we are unable to give you more information 
about when this is likely to happen. 
 
5. What do I have to do? 
 
Your hospital stay, medication, investigations or future follow up with us/ your 
GP is not altered in any manner.  
There are no life style or dietary restrictions on the participating patients. You 
can drive; drink and take part in sport and other social activities as per your 
wish. You can continue all your medications as usual. 
 
6. What are the side effects of any treatment received when taking part? 
 
Your will not be given any treatment as part of this research study and so we 
don’t expect you to have any side effects from this study. 
 
7. What are the possible disadvantages and risks of taking part? 
 
Your participation in this research does not subject you to any additional risks 
on its own. The risks associated with the camera test/ operation are the same 
whether you participate in the research or no. 
 
Also we will not be identifying any new diseases from this study. 
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8. What are the possible benefits of taking part? 
 
There are no immediate benefits from taking part in this study. 
 
Through this research we are trying to find out if some of the chemical 
substances associated with cancer tissue tell us about the future course of 
the disease and response to various treatments. This information may help 
us in knowing beforehand about the prognosis of a particular patient (and at 
present we do not have sufficient information to advice you about your 
particular case). In long run this information might be utilised to find other 
effective treatments for cancer of the gullet. However, this cannot be 
guaranteed.  
 
9. What if new information becomes available? 
  
Sometimes during the course of a research project, new information 
becomes available about the disease, which might be applicable to you. If 
this happens, your research doctor will tell you about it and discuss with you 
whether you want to continue in the study. If you decide to withdraw your 
research doctor will make arrangements for your care to continue. If you 
decide to continue in the study you will be asked to sign an updated consent 
form. 
 
Also, on receiving new information your research doctor might consider it to 
be in your best interests to withdraw you from the study. He/she will explain 
the reasons and arrange for your care to continue.  
 
10. What happens when the research study stops? 
 
This will not make any difference to your clinical care. 
 
11. What if something goes wrong? 
 
If you are harmed by taking part in this research project, there are no special 
compensation arrangements. If you are harmed due to someone’s 
negligence, then you may have grounds for a legal action but you may have 
to pay for it. Regardless of this, if you wish to complain, or have any concerns 
about any aspect of the way you have been approached or treated during the 
course of this study, the normal National Health Service complaints 
mechanisms should be available to you.  
 
12. Will my taking part in this study be kept confidential? 
 
All information that is collected about you during the course of the research 
will be kept strictly confidential. Any information about you that leaves the 
hospital/ surgery will have your name and address removed so that you 
cannot be recognised from it. 
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Your own GP will be notified of your participation in the trial if you agree to 
this. This includes other medical practitioners not involved in the research but 
who may be treating you. 
13. What will happen to the results of the research study? 
 
We hope to share the findings of the study with other doctors and NHS 
managers by presenting the findings at meetings and by publishing scientific 
articles that describe the study and results. You will not be identified in any 
report/ publication. You may be informed of the results if appropriate to your 
care. 
 
We cannot give you the likely date of the publication of results at this time.  
 
14. Who is organising and funding the research? 
 
The clinical care will be provided by the NHS, as it would normally be. The 
money for the laboratory tests will be provided by the Oesophageal Cancer 
Support Group. 
 
15. Who has reviewed the study? 
 
The Research Approval Board at the South Tees Hospitals NHS Trust and 
the South Tees Local research Ethics Committee approve all research 
studies that will be carried out in the trust hospitals. 
 
16. Contacts for further information 
 
Mr Y K S Viswanath and Mr P A Davis are the clinicians whom you can 
approach for further information about this study. The other members of the 
surgical team treating you may be involved in this project either directly or 
indirectly. 
 
Kindly address your communication to Mr P C Munipalle, Clinical research 
Fellow in Surgery at The James Cook University Hospital: 
 
Mr P C Munipalle 
Clinical research Fellow in Upper GI Surgery 
Surgical Directorate 
The James Cook University Hospital 
Marton Road 
Middlesbrough TS4 3BW 
 
Or you can discuss with him/ or one of the team members in person when 
you come for your operation/ camera test. 
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 Thank you for spending your valuable time on going through this 
leaflet. We will talk to you again at he time of your admission for your 
operation and answer any questions you might ask. 
 
 If you are willing to participate in this research you will be asked to 
sign another form before we include you in our research project. A 
copy of the form is enclosed herewith and if you wish you can sign this 
form now and bring it with you to the hospital where we will collect this 
from you and give you a copy. You can keep this patient information 
sheet. 
 
 If you wish so kindly discuss this with friends and family before 
agreeing to participate and signing the consent form. 
 
 You have every right to decline to participate in this research project. 
You can withdraw your consent later at any stage even though you 
have consented now.    
 
Thank you very much in anticipation of your co-operation. 
 
Mr P C Munipalle  
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Appendix 5 – Consent Form 
 
Centre Number: 
Study Number: 
Patient Identification Number for this trial: 
 
CONSENT FORM 
 
(Version 2: 6 Dec 2004) 
 
Title of Project: ‘Expression of Hypoxia Induced Factor 1 alpha as a prognostic 
indicator of long time survival in oesophageal cancer’ 
 
Name of Researcher: P C Munipalle 
 
       Please initial box 
 
1. I confirm that I have read and understand the information sheet dated  
6 December 2004: version 2 for the above study and have had the opportunity to 
ask questions.           
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights being 
affected.           
 
3. I understand that my participation in this project would be informed to my GP 
and other medical practitioners treating me. 
 
 I give permission for these individuals to have access to my records.  
  
 
4. I agree to take part in the above study.      
 
       
______________________ _________________ _____________ 
Name of Patient Date Signature 
 
 
_________________________ ________________ ______________ 
Name of Person taking consent Date Signature 
(if different from researcher) 
 
 
_________________________ ________________ ______________ 
Researcher Date Signature 
 
 
 
 
 1 for patient; 1 for researcher; 1 to be kept with hospital notes 
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Appendix 6 - Leica Processing Schedule 
 
Equipment – Leica TP 1050 issue processing machines 
 
Reagent Station Time Temp P/V Drain Stir 
  Hr:Min OC P/V Secs  
Formalin 1 00:30 45 P/V 120 ON 
70% Alcohol 2 00:45 37 P/V 120 ON 
90% Alcohol 3 00:45 37 P/V 120 ON 
Abs Alcohol 4-7 01:15 37 P/V 120 ON 
Abs Alcohol 4-7 01:15 37 P/V 120 ON 
Abs Alcohol 4-7 01:15 37 P/V 120 ON 
Abs Alcohol 4-7 01:15 37 P/V 120 ON 
Xylene 8-10 01:15 37 P/V 120 ON 
Xylene 8-10 01:15 37 P/V 120 ON 
Xylene 8-10 01:15 37 P/V 120 ON 
Wax Left 01:00 62 P/V 120 ON 
Wax Middle 01:00 62 P/V 120 ON 
Wax Right 01:30 62 P/V 120 ON 
 
Health and Safety 
 
1. Wear safety spectacles. Nitrile gloves are recommended but due to the 
manual dexterity required, latex gloves are acceptable provided they are 
changed frequently. 
2. Use ventilated bench when changing solutions 
3. Spillage  
CHEMICAL WATER CHEMICAL GRANS Fo GRANS & RESP 
Formaldehyde   X 
Alcohol X   
Xylene   X  
Wax SET & SCRAPE   
 
4. Hazard 
Formaldehyde: Toxic Harmful 
Xylene: Flammable Harmful 
Wax: Flammable 
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Appendix 7 - Staining protocol worksheet 
 
Step   Reagent   Duration  Test       Control 
(Minutes) 
1  Target retrieval 
2  TBS wash    5 _____         _____   
 
3  Reagent 1 (Peroxidase Block) 5 _____         _____ 
4  TBS wash    5 _____         _____ 
 
5  Reagent 2 (Protein Block)  5 _____         _____ 
 
6  Reagent 3 (Primary Antibody) 60 _____         _____ 
(or TBS for negative control) 
7  TBS wash    5 _____         _____ 
8  TBS wash    5 _____         _____ 
9  TBS wash    5 _____         _____ 
 
10  Reagent 4 (Link Antibody)  15 _____         _____ 
11  TBS wash    5 _____         _____ 
12  TBS wash    5 _____         _____ 
13  TBS wash    5 _____         _____ 
 
14  Reagent 5    15 _____         _____ 
  (Streptavidin-Biotin Complex) 
15  TBS wash    5 _____         _____ 
16  TBS wash    5 _____         _____ 
17  TBS wash    5 _____         _____ 
 
18  Reagent 6 (Amplification reagent) 15 _____         _____ 
19  TBS wash    5 _____         _____ 
20  TBS wash    5 _____         _____ 
21  TBS wash    5 _____         _____ 
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22  Reagent 7 (Streptavidin-Peroxidase) 15 _____         _____ 
23  TBS wash    5 _____         _____ 
24   TBS wash    5 _____         _____ 
25  TBS wash    5 _____         _____ 
 
26  Reagent 8 (DAB chromogen)  5 _____         _____ 
27  Rinse in distilled water 
 
28  Reagent 11 (Haematoxylin counterstain) _____         _____ 
29  Rinse in distilled water   _____         _____ 
 
30  Mounting     _____         _____
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Appendix 8 - HIF Expression Data 
Participant Observer 1 (D.S.) Observer 2 (P.C.M.) Averege score
1 0 0 0
2 39 37 38
3 0 0 0
4 12 8 10
5 41 58 49.5
6 12 6 9
7 0 0 0
8 21 57 39
9 29 41 35
10 0 0 0
11 0 2 1
12 34 33 33.5
13 42 32 37
14 19 16 17.5
15 0 0 0
16 36 24 30
17 4 3 3.5
18 28 13 20.5
19 0 1 0.5
20 5 4 4.5
21 14 8 11
22 0 0 0
23 4 2 3
24 0 7 3.5
25 12 35 23.5
26 32 29 30.5
27 44 47 45.5
28 0 0 0
29 41 34 37.5
30 15 13 14
31 6 4 5
32 1 1 1
33 24 38 31
34 17 19 18
35 2 5 3.5
36 38 41 39.5
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Appendix 9 – Original Article published in ‘Diseases of the Esophagus’ 
Title:  Prognostic value of Hypoxia inducible factor 1α in esophageal 
squamous cell carcinoma 
 
Authors:  P C Munipalle, Y K S Viswanath, P A Davis, D Scoones 
 
Address:  Department of General Surgery 
  The James Cook University Hospital 
  Middlesbrough TS8 9XN 
  Cleveland  
UK 
 
Email:  yks.viswanath@stees.nhs.uk 
Phone: +44 1642 854863 
Fax:  +44 1642 282872 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract: 
Introduction 
Hypoxia Inducible Factor 1α (HIF 1α) plays a major role in the pleitropic response 
observed secondary to hypoxic conditions in tumors. Its expression in the tumor cells 
has been correlated to tumor aggressiveness and prognosis in squamous cell 
carcinoma (SCC) of the esophagus in Far Eastern population
1
, but limited 
information is available on the prognostic role of HIF 1α in SCC of esophagus in 
European population. This information may help in choosing appropriate therapeutic 
strategies and possibly developing a monoclonal antibody with therapeutic potential 
targeting the HIF 1α.  
Methods 
Tumor samples from 36 patients diagnosed with SCC of the esophagus were 
collected. Prepared tissue sections were stained with validated and specific 
monoclonal antibodies for HIF 1α and the expression was correlated with the disease 
pattern and survival. 
Results 
Out of 36 patients, 17 patients showed low and 19 high expression of HIF 1α. There 
was no difference in the disease free and overall survival between these two groups 
(p>0.05, log rank test). Regression analysis showed that HIF 1α was not an 
independent prognostic factor for survival (p>0.05).  
Conclusion 
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HIF 1α did not show prognostic value in squamous cell carcinoma of esophagus in 
our study on European population, in agreement with previous studies. Novel 
strategies on the therapeutic manipulation of HIF 1α in cancer are to be explored 
further and may have a role to play in improving treatment outcome. 
 
 
Key words: Esophageal squamous cell cancer, Hypoxia inducible factor 1α, 
prognostic factor 
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Introduction 
Esophageal cancer is a disease on the rise yet with no major improvement in 
mortality rates, despite the advances in treatment
2
. Among Western Europe the 
incidence is highest in the North east of England in the United Kingdom, with five 
year survival of only 8%
3
. Survival may be improved by identifying potential sub-
populations of patients with better prognosis and targeting them with multi-modality 
therapy where applicable
4
. This strategy can avoid the significant morbidity caused 
by the intensive neoadjuvant, adjuvant and radical surgery treatment strategies in 
those sub-populations with poorer prognosis, who are unlikely to benefit from such 
treatments. 
The current best prognostic indicator in esophageal cancer is TNM clinical staging
5
. 
Other indicators which are recently under consideration are epidermal growth factor 
receptor (EGFR), Angiogeneic factors such as vascular endothelial growth factor, the 
tumor suppressor gene p53, cell cycle regulators, apoptotic factors and matrix 
metalloproteinases
4
. There is therefore a potential to identify more accurate 
prognostic indicators to aid in the management of esophageal cancer.     
Hypoxia inducible factor 1α (HIF 1α) belongs to the PAS (Per, ARNT, Sim) 
subfamily of basic-helix-loop-helix (bHLH) family of transcription factors
6
. To date, 
the transcription of more than 70 genes are found to be directly regulated by HIF 1α. 
These genes are involved in processes that act to address the cellular hypoxia by 
decreasing oxygen dependence and consumption by cells, and by increasing the 
efficiency of oxygen delivery to cells. These processes include vasculogenesis and 
angiogenesis, metabolism, vasodilatation, cell migration, signaling and cell fate 
decisions. Many of these processes are implicated in solid tumor survival in a 
hypoxic environment. In fact, HIF 1α expression is shown to be of prognostic value 
in many human cancers
7, 8
.   
In the present study we examined the expression pattern of HIF 1α in squamous cell 
carcinoma (SCC) of esophagus in European population and investigated its 
prognostic value.   
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Material and Methods 
The project was approved by the Research approval board & Research ethics 
committee of South Tees NHS Trust, UK and carried out at the James Cook 
University Hospital, Middlesbrough, UK. We examined tumor samples from 36 
consenting patients diagnosed or treated with SCC of esophagus between June 2005 
– August 2006. The follow up of surviving patients at the time of analysis in June 
2009 was 34 - 48 months (median 40 months).   
Histological diagnosis, grading and N staging was done on haematoxylin-eosin 
stained sections. Lymph node sections were stained where available. HIF 1α 
expression was estimated in the tissues as below: 
Immunochemistry: 
The sections were deparaffinised and rehydrated. Heat mediated epitope was used for 
antigen retrieval. Peroxidase was quenched with 3% Methanol in H2O2 for 5 minutes. 
Serum-free protein in Phosphate Buffered Saline was used for 5 minutes as protein 
block. Primary antibodies (Mouse monoclonal antibody to HIF 1α at 1:1000 
concentration, Novus Biologicals, UK) were applied to the test slides for 60 minutes 
followed by TrisBufferSaline (TBS) wash. Sections were incubated with secondary 
antibody (Biotinylated rabbit anti-mouse immunoglobulins, Dako, UK) for 15 
minutes followed by TBS wash. Sequential 15 minute incubations with Streptavidin-
Biotin-Peroxidase Complex, amplification reagent, and Streptavidin-Peroxidase 
followed by TBS wash were done. The colour was developed by 15 minute 
incubation with DAB chromogen and the sections were weakly counterstained with 
haematoxylin.  
Sections from a high grade Renal Cell Carcinoma with very high HIF 1α expression 
were used as positive controls. TBS was substituted for primary antibody as the 
negative control. 
Expression of HIF 1α in the SCC cells was determined by the strength of the nuclear 
staining to HIF 1α antibody. Under × 400 magnification, the percentage of tumor 
cells in that field which stain positive for HIF 1α compared to those cells staining 
negative was visually scored. The expression of HIF 1α in all the slides was scored 
independently by the authors (P C M and D S) who were blinded to the staging of the 
tumors. The average score of expression is used to categorise the samples, based on 
previously reported studies
1. The samples where ≥10% SCC cells showed positive 
staining were scored as ‘High’ expression and the samples with <10% SCC cells 
with positive staining were scored as ‘Low’ expression (Figure 1). 
Patient demographics, disease specific and survival data were collected from cancer 
information system and case notes. Disease free survival was defined as the time 
interval from the end of primary therapy until the first evidence of progression of the 
disease. Overall survival was defined as the time interval from the end of primary 
therapy till the last known survival date or death.  
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Statistical analysis: 
Cohen's kappa was used to measure the agreement between the two independent 
scorers. A value of 1 is considered as perfect agreement. Pearson’s 2 test or Fisher’s 
exact test were used for testing relationships between categorical variables. Survival 
curves were plotted using the method of Kaplan-Meier, and the log-rank test was 
used to determine the statistical significance. Cox proportional hazard regression 
model was used to assess the effects of patient and tumor variables on survival. 
Statistical analysis and graphic representation were performed using SPSS version 13 
(SPSS, Chicago, Illinois, USA). P < 0.05 was considered significant. 
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Results 
The study population comprised 15 males and 21 females, with a median age of 76 
years (range 52 – 95). Seventeen patients expressed low levels of HIF 1α while 19 
expressed high levels.   
The correlation between various clinicopathological variables and the expression of 
HIF 1α in the tumor is summarised in Table 1. 
Expression of HIF 1α was significantly higher in study population aged above 70 
years (p=0.02). There was a trend towards higher expression in advanced stage of the 
disease, nearing statistical significance (p=0.06). 
There was good agreement between the two independent observers regarding the 
reading of the expression of HIF 1α (Cohen’s Kappa 0.82, p<0.01).  
Survival analysis: 
Eight of the 36 patients were alive at the end of the follow up period spanning 4 
years, with an overall survival rate of 22% (Survival range 252 – 1495 days). The 
survival of the 28 patients who died in this period ranged from 32 – 1700 days. 
The median overall survival was 232 days after diagnosis. The survival rate at the 
end of 1 year was 33.3%, 2 years was 25%, 3 years was 25% and 4 years was 
22%. The 17 patients with a low expression of HIF 1α had a mean (median) 
survival of 438 (238) days with a 4 year survival rate of 18 %. The mean (median) 
survival for the 19 patients with high expression were 533 (196) days with a 4 
year survival rate of 26%. Figure 2 shows the Kaplan-Meier curve plotted for HIF 
1α expression. The censored data corresponds to those still alive at the end of the 
study period. 
There was no statistically significant correlation between the overall survival rate and 
the strength of expression of HIF 1α (p = 0.908, log rank test).  
Table 2 shows the results of the Univariate analysis of various factors. The aim of 
treatment which reflects the stage of the disease and the status of metastases were the 
only significant risk factors. HIF 1α expression was not a risk factor.  
Multivariate analysis showed only the aim of the treatment as independent prognostic 
factor (p<0.001). 
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Discussion 
Our study is the first reported study on European population with patient and disease 
characteristics different from the previous studies.  
As aggressive tumors grow rapidly and the angiogenesis cannot keep up with the 
demand for oxygen and nutrients, the central part could become hypoxic. The tumors 
recruit various mechanisms to adapt for this
9. HIF 1α is a master regulator of this 
adaptive response and hence is integral in the malignant potential of tumors. HIF 1α 
has been shown as a key factor in regulation of VEGF and VEGFR and other 
angiogenic factors, which play a major role in tumor survival and spread. A variety 
of proteins targeted by HIF 1α are involved in tumor cell proliferation, survival, 
adhesion and mobility, implicating the role of HIF 1α in these processes. Genetic 
events facilitating tumor survival and spread like deficiency or mutation of tumor 
suppressor genes (VHL, p53 and PTEN), and amplification of oncogenes (Akt, Ras, 
ERK1/2) were shown to be associated with HIF 1α overexpression in previous 
studies
10
. Bos et al
11
 showed that HER-2 immunoactivity and gene amplification, 
VEGF expression, and Ki-67 expression are correlated strongly with HIF 1α 
positivity in lymph node negative breast carcinoma. 
Most cancers over-expressing HIF 1α are associated with increased mortality. These 
include breast, stomach, brain, ovarian, endometrial, cervical, prostate and colon 
cancers
7
. In head and neck and non-small cell lung cancers, studies have shown 
conflicting results, probably due to the interaction of HIF 1α with apoptotic genes. 
The effect of HIF 1α expression probably depends on the interplay between inherent 
malignant potential of the tumor and various genetic elements.  
HIF 1α showed increased association with venous invasion, VEGF expression and 
tumor microvessel density in SCC of esophagus
1
, suggesting more aggressive course 
of the disease in tumors with high expression of HIF 1α. In addition, HIF 1α 
probably plays a role in lymphatic spread of SCC through the induction of vascular 
endothelial growth factor C
12
. Our study has shown significantly higher expression 
of HIF 1α in the SCC tumors of patients aged above 70 years although this was not 
translated to decrease in survival. We noticed clear trend of higher expression in 
patients with advanced stage of SCC, which may suggest more aggressive disease. 
This knowledge may help in choosing appropriate treatment strategy for this sub-
population, avoiding intensive therapies which can cause significant morbidity 
without much clinical benefit. Further studies evaluating the role of HIF 1α 
expression in influencing the treatment planning shall be considered.  
HIF 1α expression in SCC of esophagus did not show independent prognostic value 
in predicting overall survival in many previous studies. Kurokawa et al
13
 showed in 
their study that HIF 1α expression was a risk factor but not an independent 
prognostic factor of survival. High expression of HIF 1α in SCC was found to have a 
significant effect on disease free survival but not on overall survival
14
. A recent study 
by Yongshun et al
15
 did not show significant role for HIF 1α in predicting survival. 
Ling et al 
16
 showed that HIF 1α mRNA or protein expression did not correlate with 
histomorphological regression or survival following neoadjuvant chemotherapy for 
SCC. Our results at the end of 4 year follow-up period suggest similar role for HIF 
1α in the prognosis of SCC of esophagus. 
Our study has shown better overall survival in patients treated with curative intent 
and with no evidence of metastatic spread at the time of diagnosis. The overall 
survival figures in our study population mirror those reported from other SCC 
treatment centers in Western world. 
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Expression of HIF 1α in esophageal cancer was shown as a predictor of response to 
Photodynamic therapy
17
 and chemoradiotherapy
18
. Recently reported novel strategies 
on the role of therapeutic manipulation of HIF 1α in cancer8, 19, 20 may encourage 
further studies in this area.  
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Figure legends: 
Figure 1: Expressions of HIF 1α expression in SCC of oesophagus (× 200, × 
400). The arrow shows positively stained nucleus. 
Figure 2: Kaplan-Meier survival curve of 36 patients stratified for HIF 1α 
expression. 
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Table 1: Correlation of HIF 1α expression with clinicopathological variables 
Variable  Total  Low expression of  High expression of   p value 
    HIF 1α     HIF 1α   
Gender  36  17   19   0.709 
Male  15  7   8    
Female  21  10   11 
 
Age  36  17   19   0.022* 
<70  18  12   6    
>70  18  5   13 
 
T stage  36  17   19   0.408 
T1  2  2   0 
T2  6  2   4 
T3  16  8   8 
T4  12  5   7   
 
N stage  36  17   19   0.846 
N0  9  4   5 
N1  24  12   12 
N2  3  1   2 
 
M stage  36  17   19   0.238 
M0  24  13   11  
M1  12  4   8 
 
UICC stage 36  17   19   0.067 
Stage I  2  2   0 
Stage IIA  4  0   4 
Stage IIB  1  1   0 
Stage III  17  10   7 
Stage IV  12  4   8 
 
Tumor grade 36  17   19   0.221 
Well diff  9  2   7 
Moderately diff 7  4   3 
Poorly diff 20  11   9 
  
Aim of treatment 36  17   19   0.169* 
Curative intent 15  9   6 
Palliative intent  21  8   13 
 
* Fisher’s exact test 
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Table 2: Univariate analysis of factors associated with overall survival in patients 
with SCC of esophagus 
Variable  No. of patients Median overall survival p value 
  (n = 36)  (days)   
 
HIF expression      0.908  
Low  17  238    
High  19  196 
 
Gender       0.285    
  
Male  15  182     
Female  21  272  
 
Age (years)      0.350    
  
<70  18  240        
>70  18  176       
 
T stage       0.192     
T1  2  110       
T2  6  242   
T3  16  272 
T4  12  182  
 
N stage       0.171 
N0  9  238        
N1  24  197 
N2  3  80 
 
M stage       0.051 
M0  24  272      
M1  12  162  
 
Integrated TNM stage     0.122    
  
Stage I  2  110  
Stage IIA  4  1700 
Stage IIB  1  240 
Stage III  17  282 
Stage IV  12  162 
 
Tumor grade      0.194    
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Well diff  9  240  
Moderately diff 7  147 
Poorly diff 20  236 
  
Aim of treatment      0.001    
Curative intent 15  646  
Palliative intent  21  176 
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Figure 1: 
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Figure 2: 
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Appendix 10 
Prognostic relevance of Hypoxia Inducible Factor (HIF 1 α) expression in squamous 
cell carcinoma of oesophagus 
P C Munipalle, A Ahitan, P A Davis, YKS Viswanath 
Upper Gastrointestinal Regional Audit Day, Wynyard, UK (2008) Oral presentation 
 
Introduction 
Hypoxia Inducible Factor (HIF 1 α) plays a major role in the pleitropic response 
observed in response to hypoxic condition of tumours. Its expression is correlated to 
the aggressiveness of various tumours but its prognostic relevance in squamous cell 
carcinoma of oesophagus is unclear. This information may help in choosing between 
therapeutic strategies such as intensive combined modality therapy vs. palliative 
therapy.  
Methods 
All the patients diagnosed with squamous cell carcinoma of oesophagus over a 
period of 3 years in our tertiary oesophago-gastric centre are recruited in this 
prospective study, with a median follow-up of 28 months. The cancerous tissue 
specimens are stained with specific monoclonal antibodies for HIF 1 α and the 
expression is correlated with the disease pattern. 
Results 
Based on the pattern of HIF 1 α expression, 36 patients are divided into low (n=17) 
and high (n=19) expression groups. There is no difference in the disease free and 
overall survival between these two groups (p>0.05, log rank test). Multiple 
regression analysis showed that HIF 1 α is not an independent prognostic factor for 
squamous cell carcinoma of oesophagus (p>0.05).  
Conclusion 
HIF 1 α did not show promising prognostic relevance in this study. To improve the 
results in oesophageal cancer there is a constant need to identify better prognostic 
indicators through further molecular studies. 
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Appendix 11 
Association of Surgeons of Great Britain and Ireland International Surgical Congress, Glasgow, UK (May 2009) Poster presentation 
 
